Cyalume Technologies (CYLU) Inactive 10-K31 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Mar. 23, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	Cyalume Technologies Holdings, Inc.
Entity Central Index Key	1335293
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$1,049,070
Trading Symbol	CYLU
Entity Common Stock, Shares Outstanding		21,400,244

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Current assets:
Cash	$2,358		$865
Accounts receivable, net of allowance for doubtful accounts of $22 and $44, respectively	3,622		3,788
Inventories, net	7,826		10,782
Income taxes refundable	0		163
Deferred income taxes - current	0		3,847
Prepaid expenses and other current assets	648		463
Total current assets	14,454		19,908
Property, plant and equipment, net	7,120		8,001
Goodwill	7,992	[1]	7,992	[1]
Other intangible assets, net	6,591		17,948
Other noncurrent assets	18		465
Total assets	36,175		54,314
Current liabilities:
Line of credit	2,050		1,600
Current portion of notes payable	5,775		1,925
Accounts payable	2,144		6,182
Accrued expenses	2,690		2,059
Deferred revenue and deferred rent	181		80
Income taxes payable	644		97
Current portion of capital lease obligation	7		15
Warrants liability	25		6,373
Legal obligation	0		3,986
Other current liabilities	0		242
Total current liabilities	13,516		22,559
Notes payable, net of current portion	10,214		14,969
Note payable due to related parties	2,100		2,100
Deferred income taxes	430		3,847
Asset retirement obligation	204		194
Capital lease obligation, net of current portion	0		7
Legal obligation, noncurrent	2,781		0
Other noncurrent liabilities, net of current portion	78		79
Total liabilities	29,323		43,755
Commitments and contingencies (Note 18)
Stockholders' equity
Series B convertible preferred stock, $0.001 par value; 1,000,000 shares of preferred stock authorized; 1,000 shares issued and outstanding at December 31, 2014	1,401		0
Common stock, $0.001 par value; 100,000,000 shares authorized; 21,400,244 and 20,738,260 issued and outstanding at December 31, 2014 and 2013, respectively	21		21
Additional paid-in capital	103,014		102,575
Accumulated deficit	-103,590		-95,874
Accumulated other comprehensive loss	-661		-218
Total stockholders' equity	185		6,504
Total liabilities and stockholders' equity	36,175		54,314
Series A Convertible Preferred Stock [Member]
Temporary Equity
Temporary Equity	4,564		4,055
Series C Preferred Stock [Member]
Temporary Equity
Temporary Equity	2,103		0
Stockholders' equity
Total stockholders' equity	$2,103		$0

[1]	Gross amount of goodwill was approximately $67.7 million as of December 31, 2014 and 2013. Accumulated impairment losses were approximately $59.7 million as of December 31, 2014 and 2013.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounts receivable, allowance for doubtful accounts	$22	$44
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	21,400,244	20,738,260
Common stock, shares outstanding	21,400,244	20,738,260
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	123,077	123,077
Preferred stock, shares outstanding	123,077	123,077
Series C Preferred Stock [Member]
Preferred stock, par value	$0.00
Preferred stock, shares authorized	1,000,000
Preferred stock, shares issued	1,000
Preferred stock, shares outstanding	1,000
Series B convertible preferred stock [Member]
Preferred stock, par value	$0.00
Preferred stock, shares authorized	1,000,000
Preferred stock, shares issued	1,000
Preferred stock, shares outstanding	1,000

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Revenues	$33,322	$31,760
Cost of revenues	19,392	17,957
Gross profit	13,930	13,803
Other expenses (income):
Sales and marketing	3,395	4,903
General and administrative	5,662	11,404
Research and development	1,506	1,864
Interest expense, net	2,086	2,310
Interest expense - related party	356	297
Amortization of intangible assets	1,812	1,796
Uncollectible receivable - related party	0	3,862
Impairment loss on intangible assets	9,580	875
Impairment loss on goodwill	0	168
Legal settlement	0	2,048
Change in fair value of contingent consideration	0	242
Change in fair value of warrants liability	-4,852	525
Loss on extinguishment of debt - related party	527	2,142
Other expenses (income), net	336	58
Total other expenses	20,408	32,494
Loss before income taxes	-6,478	-18,691
Provision for (benefit from) income taxes	1,238	-3,038
Net loss	-7,716	-15,653
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	-443	200
Unrealized gain on cash flow hedges, net of taxes of $0 and $(59), respectively	0	97
Other comprehensive (loss) income	-443	297
Comprehensive loss	-8,159	-15,356
Net loss	-7,716	-15,653
Net Income (Loss) Available to Common Stockholders
Loss available to common stockholders - basic and diluted	-13,249	-21,261
Loss per common share:
Basic and diluted (in dollars per share)	($0.62)	($1.03)
Weighted average shares used to compute net loss per common share:
Basic and diluted (in shares)	21,294,432	20,714,531
Series C Preferred Stock [Member]
Net Income (Loss) Available to Common Stockholders
Preferred stock dividends	-103	0
Series A Convertible Preferred Stock [Member]
Net Income (Loss) Available to Common Stockholders
Preferred stock dividends	-509	-55
Series A Deemed Dividend [Member]
Net Income (Loss) Available to Common Stockholders
Deemed dividend	-2,422	-5,553
Series B Deemed Dividend [Member]
Net Income (Loss) Available to Common Stockholders
Deemed dividend	-1,098	0
Series C Deemed Dividend [Member]
Net Income (Loss) Available to Common Stockholders
Deemed dividend	($1,401)	$0

Consolidated_Statements_of_Com1

Consolidated Statements of Comprehensive Loss (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Unrealized gain (loss) on cash flow hedges, taxes	$0	($59)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Series B Preferred Stock [Member]	Payment of contingent consideration liability [Member]	Payment of contingent consideration liability [Member]	Payment of contingent consideration liability [Member]	Payment of contingent consideration liability [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Other Comprehensive Loss [Member]
In Thousands, except Share data	Total	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Series B Preferred Stock [Member]	Payment of contingent consideration liability [Member]	Series A Preferred Stock [Member]	Series C Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Payment of contingent consideration liability [Member]	Additional Paid-In Capital [Member]	Payment of contingent consideration liability [Member]	Accumulated Deficit [Member]	Payment of contingent consideration liability [Member]	Accumulated Other Comprehensive Loss [Member]	Payment of contingent consideration liability [Member]
Beginning balance at Dec. 31, 2012	$25,275	$0	$0	$0					$21		$105,990		($80,221)		($515)
Beginning balance (in shares) at Dec. 31, 2012		0	0	0					20,738,260
Proceeds received from issuance of Series A and B convertible preferred stock	0	4,000	0	0					0		0		0		0
Proceeds received from issuance of Series A and B convertible preferred stock (in shares)		123,077	0	0					0
Dividends accrued on Series A and C convertible preferred stock	-55	55	0	0					0		-55		0		0
Deemed dividend on Series A convertible preferred stock	-4,000	4,000	0	0					0		-4,000		0		0
Series A,B and C convertible preferred stock issuance costs	-647	0	0	0					0		-647		0		0
Excess of common warrant and preferred warrant fair value	-1,553	-4,000	0	0					0		-1,553		0		0
Fair value of amended related party note over note face value	2,067	0	0	0					0		2,067		0		0
Shares issued to related party	0
Share-based compensation	773	0	0	0					0		773		0		0
Share-based compensation (in shares)		0	0	0					0
Net loss	-15,653								0		0		-15,653		0
Other comprehensive income	297								0		0		0		297
Ending balance at Dec. 31, 2013	6,504	4,055	0	0					21		102,575		-95,874		-218
Ending balance (in shares) at Dec. 31, 2013		123,077	0	0					20,738,260
Proceeds received from issuance of Series C preferred stock	0	0	1,000	0					0		0		0		0
Proceeds received from issuance of Series C preferred stock (in shares)		0	1,000	0					0
Proceeds received from issuance of Series A and B convertible preferred stock	1,000	0	0	1,000					0		0		0		0
Proceeds received from issuance of Series A and B convertible preferred stock (in shares)		0	0	1,000					0
Dividends accrued on Series A and C convertible preferred stock	-612	509	103	0					0		-612		0		0
Reversal of forfeited restricted awards	0	0	0	0					0		0		0		0
Reversal Of Forfeited Restricted Awards (in shares)		0	0	0					-3,333
Series A, B and C allocation of fair value	401	0	-401	401					0		0		0		0
Series A,B and C convertible preferred stock issuance costs	-321	0	0	0					0		-321		0		0
Warrants amended in connection with debt refinancing	-72	0	0	0					0		-72		0		0
Common stock issuance					241	0	0	0		0		241		0		0
Common stock issuance (in shares)						0	0	0		350,000
Shares issued to related party	157	0	0	0					0		157		0		0
Shares issued to related party (in shares)		0	0	0					242,308
Shares issued - warrant exercise	45	0	0	0					0		45		0		0
Shares issued - warrant exercise (in shares)		0	0	0					73,009
Excess of Amended JFC Note fair value over face value	483	0	0	0					0		483		0		0
Termination of USVC common and preferred warrants	1,525	0	0	0					0		1,525		0		0
Series C deemed dividends	-1,401	0	1,401	0					0		-1,401		0		0
Share-based compensation	394	0	0	0					0		394		0		0
Share-based compensation (in shares)		0	0	0					0
Net loss	-7,716								0		0		-7,716		0
Other comprehensive income	-443								0		0		0		-443
Ending balance at Dec. 31, 2014	$185	$4,564	$2,103	$1,401					$21		$103,014		($103,590)		($661)
Ending balance (in shares) at Dec. 31, 2014		123,077	1,000	1,000					21,400,244

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net loss	($7,716)	($15,653)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization of property, plant and equipment	1,367	1,387
Amortization of intangible assets, debt issuance costs and debt discount	2,050	2,429
Benefit from deferred income taxes	430	-3,328
Share-based compensation expense	394	773
Impairment loss on intangible assets	9,580	875
Impairment loss on goodwill	0	168
Change in fair value of contingent consideration	0	242
Change in fair value of derivatives	0	-14
Change in fair value of warrants liability	-4,852	525
Non-cash interest expense	1,017	159
Legal settlement	0	2,038
Uncollectible receivable - related party	0	3,862
Loss on extinguishment of debt - related party	527	2,142
Other non-cash expenses	69	127
Changes in operating assets and liabilities:
Accounts receivable	112	212
Inventories	2,818	-1,124
Prepaid expenses and other current assets	157	12
Accounts payable and accrued liabilities	-3,347	2,115
Accrued interest on note payable to related party	252	252
Deferred revenue and deferred rent	101	80
Income taxes payable	723	114
Net cash provided by (used in) operating activities	3,682	-2,607
Cash flows from investing activities:
Purchases of long-lived assets	-664	-813
Payments for intangibles	-172	-370
Proceeds from disposal of long-lived assets	0	18
Net cash used in investing activities	-836	-1,165
Cash flows from financing activities:
Net proceeds from line of credit	450	1,600
Principal payments on notes payable	-1,912	-2,621
Payments of debt issuance and deferred financing costs	-21	-163
Proceeds received from issuance of preferred stock	2,000	4,000
Payment of preferred stock issuance costs	-321	-647
Proceeds received from warrant exercise	1	0
Payment in connection with legal settlement agreements	-1,465	-275
Principal payments on capital lease obligations	-15	-14
Net cash (used in) provided by financing activities	-1,283	1,880
Effect of exchange rate changes on cash	-70	62
Net increase (decrease) in cash	1,493	-1,830
Cash, beginning of period	865	2,695
Cash, end of period	$2,358	$865

Background_And_Description_of_

Background And Description of Business	12 Months Ended
Background And Description of Business	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND DESCRIPTION OF BUSINESS	1. BACKGROUND AND DESCRIPTION OF BUSINESS

	These consolidated financial statements and footnotes include the financial position and operations of Cyalume Technologies Holdings, Inc. (“Cyalume” or the “Company”), a holding company that is the sole shareholder of Cyalume Technologies, Inc. (“CTI”) and of Cyalume Specialty Products, Inc. (“CSP”). CTI is the sole shareholder of Cyalume Technologies, SAS (“CTSAS”), Cyalume Realty, Inc. (“CRI”) and Combat Training Solutions, Inc. (“CTS”). All significant intercompany accounts and transactions have been eliminated in consolidation.

	The Company’s primary focus is providing tactical and training solutions to the military of the U.S. and other countries through both products and services.

	CTI and CTSAS manufacture and sell chemiluminescent products and reflective and photoluminescent materials to military, ammunition, commercial and public safety markets. CTSAS is located in France and represents us in certain international markets, primarily Europe and the Middle East. CTI sells to customers in all other geographic markets. CTI’s and CTSAS’ business operations constitute the majority, based on revenues and assets, of our consolidated business operations.

	CSP manufactures and sells specialty chemical products to the defense, pharmaceutical, cosmetic and other markets. CSP’s operations are located in Bound Brook, New Jersey.

	CRI previously owned land located in Colorado Springs, Colorado. The land was transferred in connection with a 2013 legal settlement (see Note 18) and therefore, this subsidiary no longer has any activity.

	CTS provides its customers with battlefield effects simulation products while its services include planning and implementing tactical training exercises simulating real-world experiences. These products allow military and law enforcement professionals to maintain operational readiness through safe, live training and hands-on situational exercises.

	Our business is managed and financial results are reported as one segment. The CEO, who is the chief operating decision maker, focuses on consolidated results to make strategic and tactical decisions. Our one operating segment consists of three reporting units: Chemical Light (the operations of CTI, CTS and CTSAS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.).

	The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. For the years ended December 31, 2014 and 2013, the Company had net losses of approximately $7.7 million and $15.7 million, respectively, and generated approximately $3.7 million of cash from its operations for the year ended December 31, 2014. The Company used approximately $2.6 million in cash flow for operating activities for the year ended December 31, 2013. As of December 31, 2014 and 2013, the Company had an accumulated deficit of approximately $103.6 million and $95.9 million, respectively, and total stockholders’ equity of $0.2 million and $6.5 million, respectively. The Company’s unrestricted cash balance was approximately $2.4 million at December 31, 2014.

	Due to uncertainty about the Company’s ability to meet its current debt obligations, in their report on our annual financial statements for the year ended December 31, 2014, the Company’s independent registered public accounting firm included an explanatory paragraph regarding the Company’s ability to continue as a going concern.

	In light of the Company’s results of operations, management has been evaluating various possibilities including but not limited to refinancing or restructuring the Company’s debt, reducing or eliminating operating expenses, and raising additional capital through the issuance of common or preferred stock or securities convertible into common stock. These possibilities, to the extent available, may be on terms that result in significant dilution to the Company’s existing stockholders, may reduce the value of the stockholders’ investment in the Company or may impact the Company’s stock price.

	There can be no assurances that the Company will be successful in raising adequate additional financial support. If not, the Company would be required to reduce operations. The Company’s consolidated financial statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2	SIGNIFICANT ACCOUNTING POLICIES

	Foreign Operations

	The accounting records of our France-based subsidiary CTSAS are maintained in Euros, their local and functional currency. For consolidation, revenue and expense transactions are translated to U.S. dollars using the average exchange rate of the month in which the transaction took place. Assets and liabilities are translated to U.S. dollars using the exchange rate in effect as of the balance sheet date. Equity transactions are translated to U.S. dollars using the exchange rate in effect as of the date of the equity transaction. Translation gains and losses are reported as a component of accumulated other comprehensive income within stockholders’ equity. Gains and losses resulting from transactions which are denominated in other than the functional currency are reported as other income or loss in the statement of comprehensive income (loss) in the period the gain or loss occurred.

	Comprehensive Loss

	Comprehensive loss accounts for changes in stockholders’ equity resulting from non-stockholder sources. All transactions that would cause comprehensive loss to differ from net loss have been recorded and disclosed and relate to (i) the translation of the accounting records of our France-based subsidiary CTSAS and (ii) the effective portion of activities designated as hedges for hedge accounting purposes.

	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are used when accounting for certain items such as reserves for inventory, accounts receivable and deferred tax assets; assessing the carrying value of intangible assets including goodwill; determining the useful lives of property, plant and equipment and intangible assets; determining asset retirement obligations; and determining the fair value of contingent consideration. Estimates are based on historical experience, where applicable, and assumptions that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved with estimates, actual results may differ.

	Accounts Receivable

	Accounts receivable are recorded at the aggregate unpaid amount less any allowance for doubtful accounts. The allowance is based on historical bad debt experience and the specific identification of accounts deemed uncollectible. An account receivable’s delinquency status is determined based on its contractual terms. Interest is not charged on outstanding balances. Accounts are written off only when all methods of recovery have been exhausted. Credit risk is controlled through initial credit evaluations and approvals, credit limits, and monitoring procedures. Ongoing credit evaluations of customers are performed but do not require collateral to secure accounts receivable.

	Inventories

	Inventories are stated at the lower of cost (on a first-in first-out (“FIFO”) method) or net realizable value. The cost of inventory consists of raw material content, labor costs to produce the inventory and overhead costs incurred during production of the inventory. The Company periodically reviews the realizability of inventory. Provisions are recorded for potential obsolescence which requires management’s judgment. Conditions impacting the realizability of inventory could cause actual write-offs to be materially different than provisions for obsolescence.

	Property, Plant and Equipment

	Property, plant and equipment are stated at cost. Depreciation is computed under the straight-line method over the estimated useful lives of four to eight years for equipment and 30 years for buildings and improvements.

	Property, plant and equipment assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Such reviews are based on a comparison of the asset’s undiscounted cash flows to the recorded carrying value for the asset. Impairment charges, if any, are recorded in the period in which the impairment is determined.

	Goodwill

	Goodwill is deemed to have an indefinite life and accordingly, is not subject to amortization. Goodwill is subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon its estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined.

	The Company performs a traditional two-step process for assessing goodwill for impairment annually. The first step of the two-step process requires a comparison of estimated fair value for each reporting unit versus the carrying or book value. If the carrying value exceeds fair value, further analysis (step 2 of the two-step process) is required to determine the amount, if any, that goodwill is impaired. Fair value is determined using a discounted cash flow analysis.

	Intangible Assets

	Intangible assets include developed technologies and patents, customer relationships, non-compete agreements, trademarks and trade names, all of which are amortized over their estimated useful lives. The carrying amounts of amortizing intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable.

	Costs incurred to register new patents or defend existing patents are capitalized, while costs to renew or extend the term of intangible assets are expensed when incurred. Costs incurred with third parties that are related to internally developing or successfully defending an intangible asset are capitalized as part of the intangible asset developed or defended and amortized over that asset’s remaining useful life. Such costs with third parties related to patent or trademark applications that are ultimately rejected by the relevant government authority are expensed upon rejection. The useful lives used for amortization of intangible assets are as follows:

			Useful lives
	Patents and developed technologies			-1
	Purchased customer relationships			9 – 13 years
	Trademarks and trade names			-2
	Non-compete agreements			5 years

		-1	Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 years thereafter. Amortization on patent costs begins when the relevant government authority approves the related patent. Patents that have been recorded as of December 31, 2014 are expected to expire by 2034. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on patents of approximately $5.3 million was recorded during 2014 (see Note 3).

		-2	Trademarks and trade names of CTI are deemed to have a useful life of 15 years. CTI’s trademarks and trade names are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on trade names of approximately $4.3 million was recorded during 2014 (see Note 3).

	Debt Issuance and Deferred Financing Costs

	Costs paid to lenders to obtain financing are presented as discounts on the related debt and are amortized to interest expense over the term of the related financing, using the effective interest method (unless the financing is a line of credit, in which case the straight-line method is used). Such costs paid to third parties are presented as assets and are amortized to interest expense in the same manner as costs paid to lenders.

	Derivatives

	Derivatives are recorded at their fair value as of the balance sheet date. If a derivative qualifies for “hedge accounting” under U.S. GAAP and has been designated as a hedge by us, then the “effectively hedged” portion is recorded, as defined by U.S. GAAP, of changes in such derivatives’ fair value in accumulated other comprehensive loss, which is a component of our stockholders’ equity. The Company records (i) ineffectively hedged portions of such changes in fair value or (ii) changes in the fair value of derivatives not designated as a hedge in our consolidated statement of comprehensive loss in the period the change occurred. On the consolidated statement of cash flows, cash flows from derivative instruments accounted for as cash flow hedges are classified in the same category as the cash flows from the items being hedged.

	Warrants Liability

	The Company uses fair values as determined by significant unobservable inputs. These estimated values are significant inputs into the Monte Carlo simulation method and the Black Scholes pricing model used to calculate the estimated fair value of common warrants and preferred warrants potentially settleable in cash, which are recorded as warrants liability. The estimated fair value of the common warrants and the preferred warrants are determined at each balance sheet date and the change in the estimated fair value of the warrants is reflected within the Company’s statements of comprehensive loss. Certain common and preferred warrants were terminated on July 30, 2014 (see Note 19).

	Revenue Recognition

Revenue from the sale of products or the providing of services is recognized when the earnings process is complete, the amount of recognizable revenue can be determined, the risks and rewards of ownership have transferred to the customer and collectability is reasonably assured. Depending on the terms of the individual sales arrangement with our customer, product sales are recognized at either the shipping point or upon receipt by the customer. Costs and related expenses to manufacture the products are recorded as costs of goods sold when the related revenue is recognized. Additionally, if the right of return is granted to the buyer in a product sale, revenue is deferred until enough historical customer data is available to reasonably estimate returns and related costs.

Two significant contracts provide for the sale of indefinite quantities of products at fixed per unit prices, subject to adjustment for certain economic factors. Revenue under these contracts is recognized when products ordered under the contracts are received by the customer. Whenever costs change, the pricing under these contracts is reviewed to determine whether they require the sale of products at a loss. To date, there are no loss contracts which would require the accrual of future losses in the current financial statements.

Research and development services are provided for customers for which the Company earns payments that are contingent upon achieving a specific result (“milestones”). Upon achieving such milestones, revenue is recognized provided that the payment is (i) related to past performance, (ii) reasonable relative to all of the deliverables and payment terms within the arrangement with our customer, and (iii) nonrefundable.

Taxes Collected from Customers

Sales taxes collected from customers are not considered revenue and are included in accounts payable and accrued expenses until remitted to the taxing authorities.

Shipping and Handling Costs

Outbound shipping and handling costs are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). These costs were approximately $358,000 and $423,000 for the years ended December 31, 2014 and 2013, respectively.

Advertising Costs

Advertising costs are expensed as incurred and are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). Advertising expense was $151,000 and $215,000 for the years ended December 31, 2014 and 2013, respectively.

Stock-Based Compensation

Stock-based compensation is incurred related to awards of common stock, restricted common stock and options to employees and non-employees. Those awards are measured at their fair value on the date the award is granted and are recognized in our consolidated financial statements over the period the grantee is required to provide services in exchange for the award. When recognized as an expense, the fair value of the award, less estimated forfeitures, is recognized on a straight-line basis over the award service period; if there is no such service period, then the entire fair value of the award is recognized as expense on the grant date.

Research and Development

The Company has research and development groups with full-time chemists and engineers at both the West Springfield and Bound Brook facilities. The research and development groups are focused on maintaining quality of existing products, developing improvements to existing products, and developing new technologies and products with viable commercial applications. Research and development costs are expensed as incurred.

Income Taxes

Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are recognized when, based upon available evidence, realization of the assets is more likely than not.

In assessing the realization of long-term deferred income tax assets, it is considered whether it is more likely than not that the deferred income tax assets will be realized. The realization of deferred income tax assets depends upon future taxable income in years before net operating loss carryforwards expire. The recoverability of deferred income tax assets is evaluated on a quarterly basis. If the Company determines that it is more likely than not that deferred income tax assets will not be recovered, a valuation allowance is established against some or all deferred income tax assets.

When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceeds the amount measured as described above, if such a position existed, would be reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. There were no such positions as of December 31, 2014 or 2013.

Interest on tax deficiencies is classified as interest expense and income tax penalties are classified as other expense.

In February 2012, an IRS audit was completed of the Company’s tax returns for the years 2008 and 2009. There were no adjustments to those tax returns. Tax returns filed for the years 2010, 2011, 2012 and 2013 are still open for audit and the 2013 tax return has been selected for examination by the IRS. The tax return for 2014 is expected to be filed under a filing extension prior to September 15, 2015.

Net Loss per Common Share

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. Potential common share equivalents consist of (i) shares issuable upon the exercise of warrants and options (using the “treasury stock” method), (ii) unvested restricted stock awards (using the “treasury stock” method) and (iii) shares issuable upon conversion of convertible notes and convertible preferred stock using the “if-converted” method.

		(in thousands, except shares and per share information)
		Year Ended December 31,
		2014			2013
Numerator (in thousands):
Net loss		$	-7,716		$	-15,653
Series A convertible preferred stock dividends			-509			-55
Series C preferred stock dividends			-103			0
Series A deemed dividend			-2,422			-5,553
Series B deemed dividend			-1,098			0
Series C deemed dividend			-1,401			0
Loss available to common stockholders – basic and diluted		$	-13,249		$	-21,261

Denominator:
Weighted average shares outstanding – basic and diluted			21,294,432			20,714,531

Loss per common share:
Basic and diluted loss per common share		$	-0.62		$	-1.03

The following potentially dilutive common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was antidilutive for each of the periods presented:

		Year Ended December 31,
		2014			2013
Options			10,347,322			2,852,186
Series A convertible preferred stock			33,401,765			6,153,850
Series B convertible preferred stock			35,713,147			0
Amended related party note			3,997,074			1,538,450
Convertible notes payable			2,666,667			2,666,667
Warrants			455,514			528,523
Restricted stock awards			0			34,266

A preferred warrant convertible into 123,077 shares of Series A preferred stock was only exercisable if 2014 earnings fell below a certain threshold. The 123,077 shares of Series A preferred stock would have been convertible into 6,153,850 shares of the Company’s common stock. The preferred warrant was terminated on July 30, 2014. The underlying 6,153,850 common shares issuable upon conversion of the Series A preferred stock relating to the preferred warrant were not included in the computation of diluted loss per common share for the years ended December 31, 2014 and 2013.

In connection with the issuance of the Company's Series A preferred stock, warrants to purchase a total of 528,523 shares of the Company's common stock were issued. If the preferred warrant became exercisable, the warrant shares pursuant to the warrants would have been increased by 174,404. The preferred warrant was terminated on July 30, 2014. The 174,404 contingently issuable warrant shares were not included in the computation of diluted loss per common share for the years ended December 31, 2014 and 2013.

Fair Value

Under U.S. GAAP, the Company is required to record certain financial assets and liabilities at fair value and may choose to record other financial assets and financial liabilities at fair value as well. Also under U.S. GAAP, the Company is required to record nonfinancial assets and liabilities at fair value due to events that may or may not recur in the future, such as an impairment event. When required to record such assets and liabilities at fair value, that fair value is estimated using an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. That fair value is determined based on significant inputs contained in a fair value hierarchy as follows:

	Level 1	Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

	Level 2	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

	Level 3	Unobservable inputs for the asset or liability.

The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

There are three general valuation techniques that may be used to measure fair value, as described below:

Market Approach	Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources.

Cost Approach	Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost).

Income Approach	Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate.

Recent Accounting Pronouncements

The following are recent accounting pronouncements that have affected our consolidated financial statements or may affect them in the future.

In July 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists (“ASU 2013-11”) to clarify that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss (“NOL”) carry-forward, a similar tax loss, or a tax credit carry-forward, with some allowed exceptions. ASU 2013-11 does not impose any new recurring disclosure requirements because it does not affect the recognition or measurement of uncertain tax positions. ASU 2013-11 is effective for fiscal years beginning after December 15, 2013. The adoption of ASU 2013-11 did not have a material impact on our financial position or results of operations.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 0214-09”). ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard will be effective for annual and interim periods beginning on or after December 15, 2016, and will be effective for the Company beginning on January 1, 2017. Early adoption is not permitted. The Company is currently evaluating the method of adoption and the potential impact the update may have on our financial position and results of operations.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 will be effective for annual and interim periods beginning on or after December 15, 2016, and will be effective for the Company beginning on January 1, 2017. Early adoption is permitted. The Company is currently evaluating the impact, if any, of the adoption of this update.

Impairment_Charges

Impairment Charges	12 Months Ended
Impairment Charges	Dec. 31, 2014
Asset Impairment Charges [Abstract]
IMPAIRMENT CHARGES	3. IMPAIRMENT CHARGES

	During 2014, the Company’s Chemical Light reporting unit recorded a loss on impairment of certain amortizing intangible assets of $9.6 million. See Note 23 for fair value information on these assets.

	During the third quarter of 2014, management conducted an annual review of tangible and intangible assets for impairment. Before assessing whether any of the Company’s reporting units’ goodwill was impaired, the Company first assessed whether any long-lived assets were impaired. This assessment determined that the CTI patent asset was impaired by approximately $5.3 million and that CTI trademarks and trade names were impaired by approximately $4.3 million. Therefore, the Company recorded a $9.6 million impairment loss on these CTI intangible assets during the third quarter of 2014.

	The “step 1” goodwill impairment assessment was performed by comparing the fair value of each reporting unit containing goodwill to those reporting units’ carrying values. The Company’s Chemical Light and Specialty Products reporting units have goodwill assets. Since there are no quoted market prices for the Company’s reporting units, the fair value of the Company’s reporting units were determined using a discounted present value technique utilizing each reporting unit’s forecasted after-tax cash flows. The “step 1” test determined that the fair value of the both the Chemical Light reporting unit and the Specialty Products reporting unit exceeded its carrying value, and therefore the goodwill did not need to be tested further under what is commonly known as “step 2” of the goodwill impairment assessment.

	Under “step 2” of a goodwill impairment assessment, the implied fair value of a reporting unit’s goodwill is compared with the carrying amount of that goodwill. If the carrying amount of the goodwill exceeds the implied fair value of that goodwill, that excess must be recognized as an impairment loss. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of a reporting unit’s goodwill. Intangible assets are identified and valued during this process, such as customer relationships, patents, trade names, non-compete agreements, and the Company’s workforce.

	During 2013, CTS recorded a goodwill impairment loss of $168,000 and a loss on impairment of certain amortizable intangible assets of $875,000. During 2012, CTI recorded a $47.1 million loss on goodwill impairment, a $281,000 loss on impairment of certain amortizing intangible assets and a $273,000 loss on impairment of certain manufacturing equipment. The Chemical Light’s trade name intangible asset was not considered to be impaired as of August 31, 2013 or as of August 31, 2012. See Note 23 for fair value information on these assets.

	During 2013, management conducted a review of tangible and intangible assets for impairment. Before assessing whether any of our reporting units’ goodwill was impaired, the Company first assessed whether any non-goodwill assets were impaired. This assessment determined that the CTS patent asset was impaired by approximately $174,000, CTS trademarks and trade names were impaired by approximately $17,000, CTS customer relationships intangibles were impaired by approximately $650,000 and CTS non-compete agreements were impaired by approximately $34,000. Therefore, the Company recorded $875,000 of an impairment loss on these CTS intangible assets during the second quarter of 2013.

	The “step 1” goodwill impairment assessment was performed by comparing the fair value of each reporting unit containing goodwill to those reporting units’ carrying values. The Chemical Light, Training, and Specialty Products reporting units have goodwill assets. Since there are no quoted market prices for our reporting units, the fair value of our reporting units were determined using a discounted present value technique utilizing each reporting unit’s forecasted after-tax cash flows. The “step 1” test determined that the carrying value of the CTS Training reporting unit exceeded its fair value, and, therefore, its goodwill needed to be tested further under what is commonly known as “step 2” of the goodwill impairment assessment. CTS did not pass the “step 1” test due to the inability to both gain traction with new products and services and attract new customers as initially planned when the reporting unit was acquired in December 2011.

	Under “step 2” of the goodwill impairment assessment, the implied fair value of CTS Training’s goodwill was compared with the carrying amount of that goodwill. If the carrying amount of the goodwill exceeds the implied fair value of that goodwill, that excess must be recognized as an impairment loss. The implied fair value of goodwill was determined in the same manner as the amount of goodwill recognized in a business combination. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied amount of the reporting unit’s goodwill. The Company identified several intangible assets that were valued during this process, including customer relationships, patents, trade names, non-compete agreements, and our workforce. The allocation process was performed only for purposes of goodwill impairment. The Company determined the fair value of these assets using various discounted cash flow-based methods that utilize assumptions such as the ability of these assets to generate future cash flows, present-value factors, income tax rates and customer attrition rates. The “step 1” calculated fair value of the CTS reporting unit was allocated to the CTS tangible and identifiable intangible assets of the CTS reporting unit at June 30, 2013 based upon the results of the “step 2” analysis, which included a full impairment to the CTS goodwill.

Inventories

Inventories	12 Months Ended
Inventories	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORIES	4. INVENTORIES

	Inventories, net consist of the following (all amounts in thousands):

		2014		2013
	Raw materials	$	4,777	$	6,535
	Work-in-process		1,546		2,185
	Finished goods		1,503		2,062
		$	7,826	$	10,782

Prepaid_Expenses_And_Other_Cur

Prepaid Expenses And Other Current Assets	12 Months Ended
Prepaid Expenses And Other Current Assets	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

	Prepaid expenses and other current assets consist of the following (all amounts in thousands):

		2014		2013
	Value added taxes receivable	$	30	$	17
	Prepaid expenses		495		312
	Debt issuance costs, current portion		21		53
	Other		102		81
		$	648	$	463

Property_Plant_And_Equipment

Property, Plant And Equipment	12 Months Ended
Property, Plant And Equipment	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	6	PROPERTY, PLANT AND EQUIPMENT

	Property, plant and equipment consist of the following (all amounts in thousands):

			2014		2013
	Land		$	1,267	$	1,285
	Building and improvements			3,564		3,332
	Machinery and equipment			8,408		8,300
	Leasehold improvements			275		266
	Furniture and fixtures			131		122
	Software			132		59
				13,777		13,364
	Less: accumulated depreciation and amortization			-6,657		-5,363
			$	7,120	$	8,001

Goodwill

Goodwill	12 Months Ended
Goodwill	Dec. 31, 2014
Goodwill, Impaired [Abstract]
GOODWILL	7	GOODWILL

	Goodwill represents the excess of the cost of acquiring CTI and CTSAS in 2008 and CSP and CTS in 2011 over the net fair value assigned to the assets acquired and liabilities assumed in those acquisitions, net of adjustments and impairment losses. Changes in the carrying amount of goodwill consist of the following (all amounts in thousands):

			CTI/CTSAS/CTS		CSP		Total
			Chemical Light				Consolidated
							Goodwill
	Balance on December 31, 2012		$	5,182	$	2,978	$	8,160
	Impairment loss (see Notes 3 and 23)			-168		0		-168
	Balance on December 31, 2013 ⁽¹⁾		$	5,014	$	2,978	$	7,992
	Impairment loss (see Notes 3 and 23)			0		0		0
	Balance on December 31, 2014 ⁽²⁾		$	5,014	$	2,978	$	7,992

		(1)(2)	Gross amount of goodwill was approximately $67.7 million as of December 31, 2014 and 2013. Accumulated impairment losses were approximately $59.7 million as of December 31, 2014 and 2013.

Other_Intangible_Assets

Other Intangible Assets	12 Months Ended
Other Intangible Assets	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
OTHER INTANGIBLE ASSETS	8. OTHER INTANGIBLE ASSETS

	Intangible assets as of December 31, 2014 consist of the following (all amounts in thousands):

					Accumulated
			Cost		Amortization		Net Book Value
	Developed technologies, including patents ⁽¹⁾		$	8,736	$	6,582	$	2,154
	Trademarks and trade names ⁽⁴⁾			1,068		401		667
	Purchased customer relationships ⁽²⁾			8,562		4,858		3,704
	Non-compete agreements ⁽³⁾			160		107		53
	Website development costs			16		3		13
			$	18,542	$	11,951	$	6,591

	Intangible assets as of December 31, 2013 consist of the following (all amounts in thousands):

					Accumulated
			Cost		Amortization		Net Book Value
	Developed technologies, including patents ⁽¹⁾		$	13,853	$	5,720	$	8,133
	Trademarks and trade names ⁽⁴⁾			5,365		119		5,246
	Purchased customer relationships ⁽²⁾			8,812		4,336		4,476
	Non-compete agreements ⁽³⁾			160		75		85
	Website development costs			8		0		8
			$	28,198	$	10,250	$	17,948

		-1	Includes a patent obtained in the acquisition of CSP with a cost of $50,000 that is expected to be fully amortized in August 2026. Patents obtained in the acquisition of CTS with an initial cost of $410,000 and a December 31, 2012 gross value of approximately $238,000 were impaired by approximately $174,000 during 2013 (see Note 3 Impairment Charges) and the $17,000 of CTS patents remaining after the impairment was transferred to CTI in 2014. The CTI patents were impaired by approximately $5.3 million during 2014 (see Note 3 Impairment Charges).
		-2	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. Customer relationships obtained in the acquisition of CTS with a cost of $840,000 was impaired by approximately $650,000 during 2013 (see Note 3 Impairment Charges) and the $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.
		-3	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016. A non-compete agreement obtained in the acquisition of CTS with an initial cost of $140,000 was impaired by approximately $34,000 in 2013 (see Note 3 Impairment Charges).
		-4	Includes CTS trade names which were impaired by approximately $17,000 in 2013 (see Note 3 Impairment Charges). Includes CTI trademarks and trade names which were impaired by approximately $4.3 million during 2014 (see Note 3 Impairment Charges).

	In 2014 and 2013, certain intangible assets were found to be impaired and their cost was reduced accordingly. See Note 3 and 24 for further discussion regarding these impairments.

	Trademarks can be renewed without substantial cost. If trademark and trade names are not renewed, then expected future cash flows associated with trademarks and trade names could be adversely affected.

	Amortization of intangible assets was $1.8 million for both years ended December 31, 2014 and 2013.

	During 2014, the Company capitalized approximately $5,000 and $160,000 of costs paid to third parties to create or defend trademarks and patents, respectively. During 2013, the Company capitalized approximately $27,000 and $342,000 of costs paid to third parties to create or defend trademarks and patents, respectively. The Company expects the patent-related costs to be amortized over approximately 20 years. The Company does not consider any intangible assets to have residual value.

	The future amortization expense relating to finite-lived intangible assets for the next five years and beyond is estimated at December 31, 2014 to be (all amounts in thousands):

	Year Ending December 31,
	2015		$	957
	2016			947
	2017			922
	2018			910
	2019			841
	Thereafter			1,894
			$	6,471

Debt_Issuance_Costs

Debt Issuance Costs	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
DEBT ISSUANCE COSTS	9	DEBT ISSUANCE COSTS

	Debt issuance costs consist of unamortized costs paid to third parties to obtain senior debt, a line of credit, convertible notes and an amended related party note that will be amortized to interest expense using the effective interest method through 2015 and 2016. Amortization of capitalized debt issuance costs was approximately $42,000 and $113,000 for the years ended December 31, 2014 and 2013, respectively.

	The future amortization expense relating to current and noncurrent capitalized debt issuance costs is approximately $27,000 and will be amortized to interest expense using the effective interest method through 2016.

Accrued_Expenses

Accrued Expenses	12 Months Ended
Accrued Expenses	Dec. 31, 2014
Payables and Accruals [Abstract]
ACCRUED EXPENSES	10. ACCRUED EXPENSES

	Accrued expenses consist of the following (all amounts in thousands):

			2014		2013
	Payroll-related ⁽¹⁾		$	834	$	1,145
	Interest payable			550		301
	Subordinated term loan exit fee			285		30
	Professional fees			87		26
	Franchise and sales tax payable			50		51
	Other			884		348
	Related party payable – Selway Capital, LLC ⁽²⁾			0		158
			$	2,690	$	2,059

		-1	Accrued payroll-related costs as of December 31, 2014 include approximately $141,000 of accrued severance costs. Accrued payroll-related costs as of December 31, 2013 include approximately $534,000 of accrued severance costs.
		-2	See Note 13 for a description of the agreement with Selway Capital, LLC.

Lines_Of_Credit

Lines Of Credit	12 Months Ended
Lines Of Credit	Dec. 31, 2014
Line Of Credit Facility [Abstract]
LINES OF CREDIT	11. LINES OF CREDIT

	The Company has a line of credit with a maximum borrowing capacity of $5.0 million with TD Bank N.A. (“TD Bank”). The amount which may be borrowed from this line of credit is dependent mainly on accounts receivable and inventory balances. Interest is payable monthly and is determined based on the Prime Rate, plus 3%. The line of credit’s interest rate at December 31, 2014 was 6.25%. The line of credit expires on December 19, 2015. This line of credit is subject to (i) the same restrictive covenants and (ii) the same collateral and guarantees as the senior debt Term Loan and the senior debt Real Estate Loan (see Note 12). At December 31, 2014, approximately $2.1 million was outstanding on this line of credit and borrowing availability was approximately $594,000 at December 31, 2014.

	CTSAS has lines of credit, for borrowing against receivables, with a combined maximum borrowing capacity of €750,000 (or approximately $900,000 as of December 31, 2014). There were no outstanding borrowings at December 31, 2014 or 2013. The lines’ interest rates are variable, based on the Euro Overnight Index Average and the 3-month Euro Interbank Offered Rate. The lines are collateralized by primarily CTSAS accounts receivable. The lines have indefinite termination dates, but can be renegotiated periodically.

Notes_Payable

Notes Payable	12 Months Ended
Notes Payable	Dec. 31, 2014
Notes Payable [Abstract]
NOTES PAYABLE	12. NOTES PAYABLE

	Outstanding notes payable consist of (all amounts in thousands):

			2014		2013
	Senior Debt - Term Loan		$	4,239	$	6,023
	Senior Debt - Real Estate Loan			1,551		1,679
	Subordinated Term Loan			9,676		8,659
	Promissory Note Payable			860		1,075
	Total			16,326		17,436
	Less: Unamortized debt discount			-337		-542
	Less: Current portion of notes payable, including current portion of unamortized debt discount			-5,775		-1,925
	Notes payable, net of current portion		$	10,214	$	14,969

	Debt issuance costs are amortized to interest expense using the effective interest method over the life of the loan.

	Senior Debt

	CTI has two loans payable to TD Bank, NA (“TD Bank”); a Term Loan and a Real Estate Loan, that were originally entered into on December 19, 2008, and which were amended twice during 2012 to modify certain financial and non-financial covenants required by these loans. The Fourth Amendment to the Amended and Restated Revolving Credit and Term Loan Agreement (the “Senior Amendment”) was entered into on November 19, 2013.

	The Term Loan is payable in monthly principal installments of $148,000 along with monthly interest payments as described below, plus a one-time principal payment of approximately $2.5 million due at maturity in December 2015.

	During 2013, interest payments on 60% of the Term Loan’s principal balance were previously hedged using a pay-fixed, receive-variable interest rate swap to reduce exposure to changes in cash payments caused by changes in interest rates on the Term Loan. The total interest rate on the swapped portion of the Term Loan was changed from 6.53% to 6.25% on December 19, 2013 and was 6.25% at December 31, 2014. Interest on the remaining 40% of the Term Loan that was not subject to an interest rate hedging relationship was at 6.25% at December 31, 2014 and at December 31, 2013. The Term Loan is collateralized by all of the assets of CTI (except CTI’s equity interests in CTSAS, of which only 65% is collateral of the Term Loan) and is guaranteed by Cyalume. The Term Loan requires various restrictive financial and nonfinancial covenants, such as a maximum leverage ratio, debt service coverage ratio and limitations on capital expenditures and dividends, with which we are in compliance as of December 31, 2014.

	The Real Estate Loan is payable in monthly principal installments of approximately $10,000, along with monthly interest payments as described below, plus a one-time principal payment of $1.4 million due at maturity in December 2015.

	During 2013, interest payments on the Real Estate Loan principal balance were hedged using a pay-fixed, receive-variable interest rate swap to reduce exposure to changes in cash payments caused by changes in interest rates on the Real Estate Loan. The Real Estate Loan’s total interest rate was changed from 6.42% to 6.25% on December 19, 2013 and was 6.25% at December 31, 2014. The Real Estate Loan is secured by a mortgage of the real property (land and building) located in West Springfield, MA, and is guaranteed by Cyalume. The Real Estate Loan requires various restrictive financial and nonfinancial covenants, such as a maximum leverage ratio, debt service coverage ratio and limitations on capital expenditures and dividends, with which the Company is in compliance with as of December 31, 2014.

	The TD Bank line of credit (see Note 11), the Term Loan and the Real Estate Loan are senior in payment priority to all other notes payable and lines of credit.

	Subordinated Term Loan

	On July 29, 2010, the Subordinated Term Loan of $8.5 million was issued to Granite Creek Partners Agent, LLC (“Granite Creek”) and on November 19, 2013, the Company entered into a Fourth Amendment to the Subordinated Term Loan (the “Subordinated Amendment”) which extended the maturity date to June 30, 2016. Pursuant to the Subordinated Amendment, interest is payable in kind through December 19, 2015 and then payable monthly in cash through the June 30, 2016 maturity date. Interest is payable monthly at a rate of 11% per annum. No principal payments are required until maturity. The Company has the right to prepay the loan in whole or in part at any time without penalty in the event that the TD Bank Senior Debt is repaid. The Subordinated Term Loan ranks junior to all debt held by TD Bank, N.A. but senior to all other remaining long-term debt including existing and future subordinated debt. The Subordinated Term Loan is convertible at any time by Granite Creek into 2,666,667 shares of common stock at a conversion price of approximately $3.19 per share. No portion of the Subordinated Term Loan has been converted to our common stock. The Company’s common stock’s closing market price on December 31, 2014 was $0.05 per share; therefore the loan’s if-converted value of approximately $0.1 million is less than the unpaid principal balance by approximately $9.5 million as of December 31, 2014. The Company previously determined that the convertible notes’ conversion feature was not a beneficial conversion feature under U.S. GAAP.

	Simultaneous with the issuance of the Subordinated Term Loan during 2010, the Company issued warrants to repay certain costs of obtaining the convertible notes. These warrants allowed the holder to purchase 160,000 shares of common stock at $1.50 per share through July 19, 2018. A portion of the $8.5 million gross proceeds from the issuance of the loan was allocated to the warrants based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at time of issuance. The portion of the proceeds so allocated to the warrants ($207,000) was recorded as a debt discount and an increase to additional paid-in capital on our consolidated balance sheet. The warrant’s fair value was increased by $94,000 in 2012 due to (i) a decrease in the exercise price of the warrants and (ii) an extension of the term of the warrant. The warrants were amended again during 2013 in connection with the Senior Amendment described above. An additional amount of approximately $241,000 was added to debt discount and warrant liability during 2013 relating to (i) another decrease in the exercise price of the warrants to $0.01, (ii) an extension of the term of the warrants, and (iii) an increase to the number of shares of common stock that may be purchased upon exercise of the warrants to 455,514 shares of common stock that may be purchased. The debt discount is being amortized to interest expense using the effective interest method over the life of the convertible notes which have a maturity date of June 30, 2016. As a result of the amendment to the warrants, the warrants are no longer indexed to the Company’s stock, are considered a derivative and therefore, are being accounted for as a liability. The warrant liability relating to the 455,514 shares of common stock which may be purchased upon exercise of the warrants is approximately $25,000 as of December 31, 2014 (see Note 19).

	The carrying value of the Subordinated Term Loan is as follows (all amounts in thousands):

			2014		2013
	Principal amount of loan		$	9,676	$	8,659
	Less: unamortized debt discount			-285		-424
			$	9,391	$	8,235

	Interest costs for the Subordinated Term Loan are as follows (all amounts in thousands):

			2014		2013
	Contractual interest coupon rate		$	1,153	$	949
	Amortization of related debt discount and debt issuance costs			221		486
	Total interest expense recognized		$	1,374	$	1,435

	The effective interest rate on the Subordinated Term loan was approximately 17% prior to the Subordinated Amendment, at which time the effective interest rate on the Subordinated Term loan became approximately 13%.

	Promissory Note Payable

	On November 19, 2013, the Company entered into a legal settlement agreement (see Note 18). The executed settlement agreement provided for the Company to make a series of payments to Antonio Colon in the amount of $215,000 annually, for a total of $1,075,000 pursuant to the Promissory Note executed on November 19, 2013 (the “Promissory Note”). This Promissory Note bears interest at a rate of 2% annually and requires principal and interest payments each May and November. The Promissory Note has a maturity date of October 15, 2018.

	Future Minimum Payments

	As of December 31, 2014, future minimum payments due for notes payable (excluding the related party note payable discussed in Note 13) for each of the five succeeding years and beyond are as follows (all amounts in thousands):

	Year Ending December 31,
	2015		$	6,005
	2016			9,891
	2017			215
2018			215
2019			0
Thereafter			0
		$	16,326

Amortization of the debt discount was approximately $205,000 and $520,000 for the years ended December 31, 2014 and 2013, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTION	13	RELATED PARTY TRANSACTIONS

	Financing Arrangements with Related Parties

	In December 2012, the Company entered into a $2,100,000 unsecured promissory note with JFC Technologies, LLC (“JFC”), an entity controlled by James Schleck, a previous employee of CSP, who is an owner of a significant amount of the Company’s common shares and is a Board member. On November 19, 2013, the unsecured promissory note was amended (the “Amended JFC Note”). Pursuant to the Amended JFC Note, interest accrues on the principal amount at the rate of 12% per annum, retroactive to the date of the original note. The entire principal amount and all accrued interest under the Amended JFC Note is due on the maturity date of December 31, 2016, or upon the refinancing of the Company’s existing indebtedness (subject to the availability of at least $5,000,000 in available credit after such repayment). Pursuant to the Amended JFC Note, up to $1.0 million of the principal amount is convertible, at the option of JFC, into the number of shares of Series A Preferred Stock equal to the portion of the principal amount being converted divided by the conversion price of $32.50 per share (subject to adjustment based on certain changes in capitalization affecting the Series A Preferred Stock). The 30,769 shares of Series A Preferred Stock, representing the total of $1.0 million of the principal amount that is convertible, is convertible into 7,318,187 shares of the Company’s common stock at a conversion price of $0.13664587 per share, as amended on July 30, 2014.

	In connection with the issuance of the Series B Convertible Preferred Stock and the Series C Preferred Stock (see Note 19), the Series A Investor and JFC entered into a Consent and Waiver Agreement with the Company, whereby the Series A Investor agreed to the termination of all of the warrants issued to it in connection with the Series A Preferred Stock and JFC agreed to terminate any right of JFC to receive any warrants otherwise issuable to it upon the conversion of any portion of the JFC Note pursuant to the terms thereof.

	In accordance with ASC 470-50-40-10, the Company analyzed the Amended JFC Note and determined that the change in the conversion price of the Series A Preferred Stock on July 30, 2014 was substantive. Therefore, the amendment to the terms of the JFC Note on July 30, 2014 resulted in a loss on extinguishment during 2014. The Company recorded a loss on the extinguishment of the Amended JFC Note of approximately $0.5 million during 2014 and also recorded a loss on the extinguishment of the original JFC Note of approximately $2.1 million during 2013, as included within “Loss on extinguishment of debt – related party” within the accompanying consolidated statements of comprehensive loss.

	On November 19, 2013, the Company issued a warrant to JFC to purchase up to 73,009 shares of the Company’s common stock, at an exercise price of $0.01. The warrant was exercised by JFC during February 2014. Bayonet Capital Fund I, LLC, Brook Industrial Park, LLC and JFC are controlled by James Schleck.

	CSP leases property in Bound Brook, New Jersey, from Brook Industrial Park, LLC. This lease requires monthly lease payments of approximately $30,000 and ends on August 31, 2016, with extension options available.

	Pursuant to an Amendment Agreement executed during December 2012, the Company is required to issue 350,000 shares of the Company’s common stock to JFC if the Company’s December 2013 common stock closing price was less than $1.75. The Company’s closing price on December 31, 2013 was $0.69. Therefore, the Company recorded approximately $242,000 within other current liabilities within the accompanying consolidated balance sheets as of December 31, 2013, and the 350,000 shares were issued to JFC on January 31, 2014.

	Agreement with Board Member

	On October 1, 2009, the Company entered into an agreement with Selway Capital, LLC (“Selway”) that provided for services to be performed by Selway on the Company’s behalf. This agreement was terminated effective March 31, 2014. The agreement previously stipulated that these services would be performed by Yaron Eitan, an employee of Selway and a member of the Company’s Board of Directors, with assistance, as needed, from other employees of Selway. Effective January 1, 2014, compensation for these services was $11,000 monthly. During April 2014, approximately $157,000 of 2013 Selway fees was settled by issuing 242,308 shares of the Company’s common stock.

Capital_Lease_Obligations

Capital Lease Obligations	12 Months Ended
	Dec. 31, 2014
Leases [Abstract]
CAPITAL LEASE OBLIGATIONS	14	CAPITAL LEASE OBLIGATIONS

	As of December 31, 2014, future minimum lease payments under capital leases together with the present value of the net minimum lease payments were approximately $7,000.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	15. INCOME TAXES

	The components of income (loss) before income taxes are as follows:

			Year Ended December 31,
			2014			2013
	Domestic		$	-7,569		$	-18,866
	Foreign			1,091			175
			$	-6,478		$	-18,691

	Provision for (benefit from) income taxes consisted of the following (all amounts in thousands):

			Year Ended December 31,
			2014			2013
	Current:
	Federal		$	223		$	0
	State			156			160
	Foreign			443			130
	Deferred:
	Federal			2,008			-2,678
	State			-1,513			-595
	Foreign			-79			-55
	Provision for (benefit from) income taxes		$	1,238		$	-3,038

	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The primary sources of these differences relate to the carrying value of identified intangible assets, inventories, fixed assets, certain accruals and reserves.

	Deferred income tax assets and liabilities consist of the following (all amounts in thousands):

			December 31, 2014					December 31, 2013
			Current			Non-current		Current		Non-current
	Deferred tax assets:
	Federal		$	2,699		$	11,857	$	6,329	$	7,230
	State			777			1,426		886		868
	Foreign			0			0		34		20
	Less: valuation allowance			-2,741			-10,353		-2,747		-3,175
				735			2,930		4,502		4,943
	Deferred tax liabilities:
	Federal			-805			-2,103		-477		-6,615
	State			-219			-538		-124		-1,697
	Foreign			-16			-414		-54		-478
				-1,040			-3,055		-655		-8,790
	Deferred tax assets (liabilities)		$	-305		$	-125	$	3,847	$	-3,847

	Principal components of our net liability representing deferred income tax balances are as follows (all amounts in thousands):

			Year Ended December 31,
			2014			2013
	Intangible assets		$	178		$	-3,778
	Property, plant and equipment			-661			-740
	U.S. loss carryforwards and tax credits, net ⁽¹⁾			10,151			8,974
	Subsidiary income ⁽²⁾			-764			-1,671
	Stock-based compensation expense			1,142			968
	Reserves, accruals and other			1,664			1,292
	State deferred tax asset			954			0
	Change in warrants fair value			0			877
	Valuation allowance			-13,094			-5,922
			$	-430		$	0

		-1	The Company had federal net operating loss carryforwards amounting to approximately $7.9 million and $13.3 million at December 31, 2014 and 2013, respectively. The net operating loss carryforward at December 31, 2014 expires in fiscal years 2026 through 2034. Internal Revenue Code Section 382 limits utilization of these losses to approximately $0.8 million per year. It is possible that future changes in ownership could result in changes to the amounts allowed by IRC Section 382. State net operating loss carryforwards amounted to approximately $10.3 million and $9.9 million as of December 31, 2014 and 2013, respectively.

		-2	A deferred tax liability has been recorded for income taxes which may become payable upon distribution of earnings of CTSAS, our French subsidiary. The estimated amount of tax that might be payable with regard to any distribution for foreign subsidiary earnings is reported net of foreign taxes paid, which are creditable against our domestic tax liability. The Company does not permanently reinvest foreign subsidiary earnings. The Company continually evaluates this assertion; if the Company’s foreign business needs change, so may this assertion.

	Income taxes computed using the federal statutory income tax rate differs from our effective tax rate primarily due to the following (all amounts in thousands):

		Year Ended December 31,
		2014			2013
Provision for federal income taxes expected at 34% statutory rate		$	-2,201		$	-6,355
Increase (reduction) resulting from:
Tax on global activities, net of foreign tax credits			-2,842			2
State income taxes, less federal income tax benefit			-895			-287
Loss on debt extinguishment			179			728
Change in valuation allowance			7,172			3,507
Change in fair value of warrants			-1,518			0
Goodwill impairment loss			0			57
Prior year true up			1,008			-715
Other			335			25
Provision for (benefit) from income taxes		$	1,238		$	-3,038

Derivative_Instruments_And_Hed

Derivative Instruments And Hedging Activities	12 Months Ended
	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	16	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

	Currency Forward Contracts

	CTSAS’ functional currency is the Euro. Periodically, CTSAS purchases inventory from CTI, which requires payment in U.S. dollars. Beginning in 2009, and only under certain circumstances, the Company utilizes currency forward contracts to mitigate CTSAS’ exposure to changes in the Euro-to-U.S. dollar exchange rate upon payment of these inventory purchases. Such currency forward contracts typically have durations of less than six months. These currency forward contracts are reported at their fair value. This relationship has not been designated as a hedge and therefore all changes in these currency forward contracts’ fair value are recorded in other income, net within the accompanying consolidated statements of comprehensive loss. There were no currency forward contracts outstanding at December 31, 2014 or December 31, 2013.

	Interest Rate Swaps

	In December 2008, the Company entered into two pay-fixed, receive-variable, interest rate swaps to reduce exposure to changes in cash payments caused by changes in interest rates on the Term Loan and the Real Estate Loan. Both relationships are designated as cash flow hedges and meet the criteria for the shortcut method for assessing hedge effectiveness; therefore, the hedge is assumed to be 100% effective and all changes in the fair value of the interest rate swaps are recorded in comprehensive income (loss). Changes due to unrealized gains and losses on the interest rate swaps must be reclassified in whole or in part into earnings if, and when, a comparison of the swap(s) and the related hedged cash flows demonstrates that the shortcut method is no longer applicable. These hedges met the criteria of the shortcut method for the duration of the hedging relationship, which ended on December 19, 2013, and therefore, the Company will not reclassify any portion of these unrealized losses from accumulated other comprehensive loss to earnings in the future.

Asset_Retirement_Obligation

Asset Retirement Obligation	12 Months Ended
Asset Retirement Obligation	Dec. 31, 2014
Asset Retirement Obligation Disclosure [Abstract]
ASSET RETIREMENT OBLIGATION	17. ASSET RETIREMENT OBLIGATION

	The Company has an obligation to remediate certain known occurrences of asbestos at our manufacturing facility in West Springfield, Massachusetts. The significant assumptions used to estimate the obligation are:

	Annual inflation rate			5.54	%
	Credit-adjusted risk-free rate			5.37	%
	Initial estimated remediation costs (undiscounted and not adjusted for inflation)			$200,000 ($41,000 paid in 2007)
	Estimated remediation completion date			19-Dec-38
	Estimated remediation cost on December 19, 2038		$	720,000

	The following is a reconciliation of the beginning and ending aggregate carrying amounts of the asset retirement obligation (all amounts in thousands):

			Year Ended December 31,
			2014			2013
	Balance, beginning		$	194		$	184
	Accretion expense			10			10
	Balance, ending		$	204	-1	$	194

		-1	The difference between the $204,000 liability as of December 31, 2014 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2014 and December 19, 2038.

	Accretion expense on the asset retirement obligation is included in general and administrative expenses in the accompanying consolidated statements of comprehensive loss.

Commitments_And_Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	18. COMMITMENTS AND CONTINGENCIES

	Operating Leases

	The Company leases certain equipment, automobiles and other assets under cancelable and non-cancelable operating leases. Expenses associated with these leases totaled $756,000 and $638,000 in 2014 and 2013, respectively.

	Included in these leases is a market-based, related-party lease which CSP assumed in conjunction with the business combination. CSP entered into the lease with an entity controlled by one of our stockholders for industrial-use property located in Bound Brook, New Jersey, U.S.A. The lease ends on August 31, 2016, with extension options available, and requires lease payments of $24,000 per month from September 1, 2011 through August 31, 2013. The monthly lease payment was adjusted to approximately $30,000 per month beginning September 1, 2013 to reflect changes in the average cost per square foot.

	Future minimum lease payments under non-cancelable lease obligations at December 31, 2014 are as follows (all amounts in thousands):

	Year Ending December 31,
	2015	$	595
	2016		480
	2017		242
	2018		59
	2019		0
	Thereafter		0
		$	1,376

	Legal

	Civil Action No. 06-706 in Superior Court of the Commonwealth of Massachusetts

	On January 23, 2006, before the Company owned CTI, the former owners of CTI (from whom CTI was purchased) (the “Former Owners”) acquired all of the outstanding capital stock of Omniglow Corporation (the “Transaction”) and changed the name of the company to Cyalume Technologies, Inc. Prior to, or substantially simultaneously with, the Transaction, CTI sold certain assets and liabilities related to Omniglow Corporation’s novelty and retail business to certain former Omniglow Corporation stockholders and management (“the Omniglow Buyers”). This was done because CTI sought to retain only the Omniglow Corporation assets and current liabilities associated with its government, military and safety business. During 2006, CTI and the Omniglow Buyers commenced litigation and arbitration proceedings against one another. Claims include breaches of a lease and breaches of various other agreements between CTI and the Omniglow Buyers. These proceedings are known as Civil Action No. 06-706 in Superior Court of the Commonwealth of Massachusetts (the “Court”).

	On December 19, 2008, while Civil Action 06-706 was still unresolved, the Company acquired CTI (the “Acquisition”). According to the Stock Purchase Agreement between the Former Owners and the Company, the Former Owners retained the responsibility for paying for all costs and liabilities associated with Civil Action No. 06-706.

	On July 18, 2011, CTI received an Order for Entry of Final Judgment in Civil Action No. 06-706 in which the Court awarded approximately $2.6 million in damages to Omniglow, LLC. Prejudgment interest at the rate of twelve (12%) percent per annum since the filing of the complaint in 2006 accrues on approximately $1.3 million of the damages. The Court also awarded Omniglow, LLC reimbursement of attorney fees and costs of approximately $235,000, on which interest at the rate of twelve (12%) percent per annum accrues beginning with the date of the final ruling.

	On July 12, 2012, the Court issued an Amended Final Judgment and, on September 20, 2012, a Final Judgment. There were no changes to the previously described damage awards. In response, on October 17, 2012, the Company filed a Notice of Appeal and on August 2, 2013, the Company filed a Formal Appeal, which contains a number of bases for overturning the awards. Oral arguments were made by the parties before the Appellate Court during January of 2014. In May 2014, the Company received notice that its appeal of the Final Judgment had been denied. On July 1, 2014, CTI filed an Application for Further Appellate Review in the Massachusetts Supreme Judicial Court.

	The Former Owners (1) previously retained the responsibility for paying the costs and liabilities associated with Civil Action No. 06-706 and (2) are related parties under U.S. GAAP due to their ownership interest in the Company and their membership on the Company’s board of directors. On November 19, 2013, a Release and Escrow Agreement was executed whereby the Company released affiliates of the Former Owners from being obligated on the costs and liabilities associated with Civil Action No. 06-706 in exchange for 625,139 shares of Cyalume stock placed in escrow (the “Escrowed Shares”). During 2013, 625,139 shares of the Company’s common stock were placed into escrow which were applied against any damages during July 2014 up to the value of the shares upon conversion to cash. The Escrowed Shares provided the Company with a source of recovery with respect to any loss, liability or expenses incurred by the Company in connection with Civil Action No. 06-706. The Company reflected the value of the 625,139 Escrowed Shares at December 31, 2013 based upon the close price of Cyalume’s stock on December 31, 2013. The value of the Escrowed Shares was previously included within the prepaid expenses and other current assets line item. The Escrow Shares were transferred during July 2014 in connection with the Confidential Settlement Agreement and Mutual Release discussed below.

	On July 10, 2014, the Company entered into a Confidential Settlement Agreement and Mutual Release (the “Omniglow Settlement Agreement”) with the Former Owners and members of management of Omniglow Corporation (collectively, the “Omniglow Buyers”). Pursuant to the Omniglow Settlement Agreement, CTI agreed to either pay the full settlement amount of approximately $4.5 million or satisfy the settlement amount as follows: (i) an initial payment of $250,000, (ii) transfer the 625,139 Escrowed Shares, (iii) payment of $1.0 million in cash within 21 days from the execution of the Omniglow Settlement Agreement and (iv) additional payments in cash and/or through cooperative marketing credits of $1.9 million if paid within 18 months from the date of the Omniglow Settlement Agreement, or of approximately $2.4 million if paid within 27 months from the date of the Omniglow Settlement Agreement. During July 2014, the Company fulfilled its obligations under items (i), (ii) and (iii) described above. Approximately $2.7 million of obligations related to this matter is included within the contingent legal obligation line items on the Company’s consolidated balance sheet as of December 31, 2014.

	Settlement of Arbitration with Former Employee

	On December 22, 2011, CTI entered into a Stock Purchase Agreement (“SPA”) with Combat Training Solutions, Inc. (“CTS”) and Antonio Colon, the sole stockholder of CTS. Pursuant to the SPA, CTI purchased all of the issued and outstanding capital stock of CTS. On June 15, 2012, the Company received a copy of a demand for arbitration filed by Mr. Colon with the American Arbitration Association. Management considered the allegations by Mr. Colon to be without merit. On August 17, 2012, Mr. Colon filed suit in Federal Court and on September 11, 2012, he filed to have the arbitration withdrawn. In addition, on September 11, 2012, Mr. Colon chose to cease working for the Company. CTI filed a Motion to Dismiss the Complaint in Federal Court and to compel the controversy to arbitration before the American Arbitration Association. The District Court for the District of Delaware held a hearing on January 23, 2013, at which it dismissed the Complaint in Federal Court without prejudice and indicated that the arbitration should proceed. On September 23, 2013, the parties entered into an agreement to resolve this matter, and a settlement agreement was signed on November 19, 2013. The executed settlement agreement provides for the Company to make a series of payments over five years to Mr. Colon in the amount of $215,000 annually, for a total of $1,075,000 pursuant to the Promissory Note executed on November 19, 2013 (see Note 12). The Company also made a settlement payment of $275,000 on November 20, 2013 and transferred the land located in Colorado (this land was originally acquired by CTI in connection with the 2011 CTS acquisition) to JasperCo, LLC pursuant to the terms of the executed settlement agreement with Antonio Colon. Pursuant to the Promissory Note, principal repayments of approximately $215,000 were made during the year ended December 31, 2014.

Preferred_Stock

Preferred Stock	12 Months Ended
	Dec. 31, 2014
Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]
PREFERRED STOCK	19. PREFERRED STOCK

	Series A Convertible Preferred Stock

	The Company is authorized to issue 1,000,000 shares of preferred stock in one or more series with such designations, voting and other rights and preferences as may be determined from time to time by our Board of Directors.

	On November 19, 2013, the Company entered into a Securities Purchase Agreement (the “Series A Purchase Agreement”) with US VC Partners, L.P. (the “Series A Investor”) for the purchase by the Investor of 123,077 units of securities of the Company for an aggregate purchase price of $4.0 million (or $32.50 per unit). Each security issued is comprised of: 1) one share of Series A Convertible Preferred Stock of the Company, at a par value of $0.001 per share (the “Series A Preferred Stock”); 2) one common stock warrant ( the “Common Warrant”); and 3) one preferred stock warrant (the “Preferred Warrant”).

	Each share of Series A Preferred Stock may be converted at any time at the option of the holder into a number of shares of common stock initially equal to 50 shares of common stock, determined by dividing the Liquidation Value per share of Series A Preferred Stock by the applicable conversion price per share of Series A Preferred Stock. The initial conversion price was equal to $0.65, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions. Pursuant to the Series A Certificate of Designation amended on July 30, 2014 (the “Amended Series A Certificate of Designation”), the conversion price per share of Series A Preferred Stock is now equal to $0.13664587. The Series A Preferred Stock is not subject to mandatory conversion at any time.

	Since the Common Warrant and the Preferred Warrant were not indexed to the Company’s stock, they were derivatives and therefore, were being accounted for as a liability. The Common Warrant and the Preferred Warrant were both terminated on July 30, 2014 in connection with the issuance of the Series B Convertible Preferred Stock and the Series C Preferred Stock discussed below. The warrants were marked to their market value of approximately $1.5 million as of July 30, 2014, at which time the liability was reclassified to equity.

	Upon voluntary or involuntary liquidation, dissolution or winding up of the Company, each holder of Series A Preferred Stock is entitled to a liquidation preference of $32.50 per share, plus any accrued but unpaid dividends, subject to customary adjustments as set forth in the Certificate of Designation (the “Series A Liquidation Value”).

	Dividends on the Series A Preferred Stock accrue (payable in cash or in kind), whether or not declared by the Board and whether or not funds are available for the payment of dividends, at a rate of 12% per annum on the sum of the liquidation preference plus all accrued and accumulated dividends and will be payable quarterly in arrears in a) cash or b) newly issued shares of Series A Preferred Stock having an aggregate liquidation preference equal to the amount of such accrued dividends (“PIK Dividends”) at the option of the Company. All accrued and accumulated dividends on the convertible preferred stock shall be paid prior to and in preference to any other class of securities of the Company.

	Each share of Series A Preferred Stock will be entitled to a number of votes equal to the number of shares of common stock into which such share is convertible and shall be entitled to vote with holders of outstanding shares of common stock, voting together as a single class, with respect to any and all matters presented to the stockholders of the Company for their action or consideration.

	The requisite holders of the Series A Preferred Stock will have the right to cause the Company to redeem, out of funds legally available, all but not less than all of the then outstanding shares of Series A Preferred Stock, for a price per share equal to the Series A Liquidation Value of such shares from and after the fifth anniversary of the closing date of the Series A Purchase Agreement. Additionally, the Company will have the right to redeem all of the outstanding shares of Series A Preferred Stock from and after the eighth anniversary of the closing date of the Series A Purchase Agreement at a redemption price equal to the Series A Liquidation Value. As a result of the redemption provisions, the Series A Preferred Stock has been classified outside of permanent equity.

	The significant change in the conversion price of the Series A Preferred Stock was determined to be a substantive qualitative change of a conversion feature that is reasonably possible of being exercised. Therefore, the amendment to the terms of the Series A Preferred Stock made on July 30, 2014 was accounted for as an extinguishment in accordance with the derecognition accounting model under ASC 260-10-S99-2. The Series A Preferred Stock fair value on the extinguishment date was estimated at approximately $1.6 million. This resulted in the Company recognizing a deemed dividend of approximately $2.4 million to reflect the Series A Preferred Stock at its July 30, 2014 redemption value.

	Series B Convertible Preferred Stock

	On July 30, 2014, the Company entered into a Securities Purchase Agreement (the “Series Band C Purchase Agreement”) with Cova Small Cap Holdings, LLC (“Cova”), Bayonet Capital Fund I, LLC, and another investor (each, an “Investor”) for the purchase by the Investors of an aggregate of 1,000 units of securities of the Company (the “Units”) for an aggregate purchase price of $2.0 million (or $2,000.00 per Unit), with each Unit comprising (1) one share of Series B Convertible Preferred Stock of the Company, par value $0.001 per share (the “Series B Preferred Stock”), and (2) one share of Series C Preferred Stock of the Company, par value $0.001 per share (the “Series C Preferred Stock”). Approximately $1.3 million of the net proceeds from the sale of the Units was used to pay a contingent legal obligation pursuant to Civil Action No. 06-706 (see Note 18).

	The shares of Series B Preferred Stock have the rights and preferences set forth in the Certificate of Designation of Series B Convertible Preferred Stock (the “Series B Certificate of Designation”). Pursuant to the Series B Certificate of Designation, each share of Series B Preferred Stock ranks senior to the Company’s common stock (the “Common Stock”) and the Company’s Series A Preferred Stock with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up of the Company. Upon the Company’s liquidation, sale to or merger with another corporation or other “Change of Control” (as such term is defined in the Series B Certificate of Designation), each share of Series B Preferred Stock would be entitled to a liquidation preference in an amount equal to the amount per share that would have been payable had all shares of Series B Preferred Stock been converted into Common Stock immediately prior to such event in accordance with the terms of the Series B Certificate of Designation, excluding for purposes of such calculation the liquidation preference payable to the holders of Series A Preferred Stock. Holders of the Series B Preferred Stock are entitled to convert at any time all or any portion of the shares of Series B Preferred Stock into a number of shares of Common Stock initially equal to 35,713.147 shares of Common Stock per share of Series B Preferred Stock (the “Conversion Number”), such that the 1,000 shares of Series B Preferred Stock issued pursuant to the Purchase Agreement will initially be convertible into a number of shares of Common Stock representing approximately 40% of the total number of shares of Common Stock outstanding, calculated on a fully-diluted basis, assuming the conversion of all outstanding shares of Series A Preferred Stock and Series B Preferred Stock. The Conversion Number is subject to customary adjustments, including for dividends, stock splits and other reorganizations affecting the Common Stock. In addition, the Conversion Number is subject to anti-dilution protections, subject to certain exceptions, if the Company issues or sells shares of Common Stock or other equity securities for no consideration or for consideration that is based on an equity valuation of the Company of less than $2 million in the aggregate (a “Trigger Issuance”). In the event of a Trigger Issuance, the Conversion Number shall be increased as of the close of business on the effective date of the Trigger Issuance to a number calculated as follows: (i) two-thirds of the Common Stock deemed Outstanding (as defined in the Series A Certificate of Designation) immediately following such Trigger Issuance (excluding any Common Stock Deemed Outstanding as a result of the conversion of the Series B Preferred Stock) (ii) divided by 1,000. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on the tenth anniversary of its original issuance date, at the then-current Conversion Number. Each share of Series B Preferred Stock is entitled to a number of votes equal to the number of shares of Common Stock into which such share is convertible and will be entitled to vote with holders of outstanding shares of Common Stock, voting together as a single class, with respect to any and all matters presented to the stockholders of the Company for their action or consideration.

	In connection with the issuance of the Series B Preferred Stock and the Series C Preferred Stock on July 30, 2014, the Company allocated the aggregate proceeds of $2.0 million to the Series B Preferred Stock and the Series C Preferred Stock on a relative fair value basis. This resulted in approximately $1.4 million allocated to the Series B Preferred Stock and approximately $0.6 million allocated to the Series C Preferred Stock. At the issuance date, the Series B Preferred Stock is convertible into Common Stock having a fair value of approximately $2.5 million, which was in excess of the proceeds allocated to the Series B Preferred Stock. Therefore, the Company recognized a beneficial conversion feature of approximately $1.1 million in accordance with ASC 470-20. This initially recorded discount was then accreted back to its carrying value of the Series B Preferred Stock as the stock is immediately convertible at the option of the holder.

	Series C Preferred Stock

	The shares of Series C Preferred Stock have the rights and preferences set forth in the Certificate of Designation of Series C Preferred Stock (the “Series C Certificate of Designation”). Pursuant to the Series C Certificate of Designation, each share of Series C Preferred Stock ranks senior to the Common Stock, the Series A Preferred Stock and the Series B Preferred Stock with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up of the Company. Upon the Company’s liquidation, sale to or merger with another corporation or other “Change of Control” (as such term is defined in the Series C Certificate of Designation), each share of Series C Preferred Stock would be entitled to a liquidation preference equal to the greater of (1) $3,000 per share or (2) $2,000 per share plus any accrued but unpaid dividends, in each case subject to customary adjustments as set forth in the Series C Certificate of Designation (the “Series C Liquidation Value”). The Series C Liquidation Value is the greater of (1) 150% of the Purchase Price ($3,000 per share) or (2) the Base Value ($2,000 per share plus accrued and unpaid dividends). Holders of the Series C Preferred Stock are entitled to cumulative quarterly dividends at a rate of 12% per annum, calculated based on an assumed price of $2,000 per share, payable in cash or in kind; provided that to the extent not paid in cash or by issuance of additional shares of Series C Preferred Stock on the last day of each calendar quarter (a “Dividend Payment Date”), all accrued dividends on any outstanding shares of Series C Preferred Stock shall accumulate and compound. In the event the Company has not paid in cash or by the issuance of additional shares of Series C Preferred Stock all accrued dividends on a Dividend Payment Date, at the election of holders of at least 75% of the outstanding shares of Series C Preferred Stock (the “Requisite Holders”), all such dividends accruing on the shares of Series C Preferred Stock will be paid in shares of Series C Preferred Stock. From and after the fifth anniversary of the issuance of the shares of Series C Preferred Stock, the Requisite Holders will have the right to elect to cause the Company to redeem, out of funds legally available therefore, all but not less than all of the then outstanding shares of Series C Preferred Stock, for a price per share equal to the Series C Liquidation Value for such shares. In addition, the Company has the right to redeem at any time, out of funds legally available therefor, all or any portion of the then outstanding shares of Series C Preferred Stock, for a price per share equal to the Series C Liquidation Value for such shares. As a result of the redemption provisions, the Series C Preferred Stock has been classified outside of permanent equity. The Series C Preferred Stock is not convertible into Common Stock or other securities of the Company, and does not have any voting rights.

	The proceeds allocated to the Series C Preferred Stock fair on the issuance date were estimated at approximately $ 0.6 million. This resulted in the Company recognizing a deemed dividend of approximately $1.4 million to reflect the Series C Preferred Stock at its July 30, 2014 redemption value.

	Common and Preferred Warrants

	In connection with the Series A Preferred Stock issued on November 19, 2013, the Company also issued a Common Warrant for the purchase of up to 6,153,830 shares of common stock at an exercise price of $0.65 per share. The estimated fair value of the Common Warrants was determined at each balance sheet date and the change in the estimated fair value of the Common Warrant is reflected within the “Change in fair value of warrants liability” within the accompanying statements of comprehensive loss.

	In connection with the Series A Preferred Stock issued on November 19, 2013, the Company also issued a Preferred Warrant for the purchase of up to 123,077 shares of Series A Preferred Stock with an exercise price of $0.05 per share. The estimated fair value of the Preferred Warrant was determined at each balance sheet date and the change in the estimated fair value of the Preferred Warrant is reflected within the “Change in fair value of warrants liability” within the accompanying statements of comprehensive loss.

	The Common Warrant and the Preferred Warrant were both terminated on July 30, 2014 in connection with the issuance of the Series B Convertible Preferred Stock and the Series C Preferred Stock discussed above. The warrants were marked to their market value of approximately $1.5 million as of July 30, 2014, at which time the liability was reclassified to equity.

	The change in the fair value of the warrants liability during the year ended December 31, 2014 is as follows (amounts in thousands):

								Subordinated
								Term Loan
		Common		Preferred				Warrants (see)		Total Warrant
		Warrant		Warrant		JFC Warrant		Note 12)		Liability
	Warrant liability at December 31, 2013	$	4,081	$	1,997	$	54	$	241	$	6,373
	Warrants amended in connection with refinancing		0		0		0		72		72
	Warrant exercise		0		0		-44		0		-44
	Change in fair value of warrants		-3,331		-1,223		-10		-288		-4,852
	Termination of Common and Preferred Warrants		-750		-774		0		0		-1,524
	Warrant liability at December 31, 2014	$	0	$	0	$	0	$	25	$	25

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	20. STOCKHOLDERS’ EQUITY

	Common Stock

	The Company is authorized to issue 100,000,000 shares of common stock. Common stockholders are entitled to one vote for each share held of record on all matters to be voted on by stockholders. Common stockholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to the common stock.

	Common Stock Purchase Warrants

	Common stock purchase warrants accounted for within equity are recorded at their initial fair value and reported in stockholders’ equity as increases to additional paid-in capital. Warrants reported as equity, rather than liabilities (i) may not be net-cash settled, (ii) have contractual limits on the number of shares to be delivered in a net-share settlement and (iii) are supported by sufficient unissued common shares available to settle the outstanding warrants. Subsequent changes in fair value from the warrants’ initial fair value are not recognized as long as the warrants continue to merit classification as equity.

	During 2012, warrants to purchase 160,000 shares of the Company’s common stock issued in conjunction with the Subordinated Term Loan were outstanding (see Note 12). These warrants were amended again during 2013 in connection with the Senior Amendment described in Note 12. As of December 31, 2014, warrants to purchase 455,514 shares of the Company’s common stock issued relating to the Subordinated Term Loan were outstanding.

	Warrants to purchase the Company’s common stock were outstanding as follows as of December 31, 2014:

			Number of			Number of
			Shares			Shares
			Exercisable			Exercisable
			Under			Under			Exercise
	Warrant Holder		Warrant			Warrant			Price			Expiration Date
	Granite Creek FlexCap I, L.P.			267,950			267,950		$	0.01		19-Nov-23
	Patriot Capital II, L.P.			187,564			187,564		$	0.01		19-Nov-23

	Share-Based Compensation

	On March 3, 2009, the Company’s Board of Directors adopted the Cyalume Technologies Holdings, Inc. 2009 Omnibus Securities and Incentive Plan (the “2009 Plan”). The Plan was approved during the Company’s Annual Meeting of Stockholders on June 18, 2009. On October 7, 2014, the Company’s Board of Directors adopted the Cyalume Technologies Holdings, Inc. 2014 Equity Incentive Plan (the “2014 Plan”). The 2014 Plan was approved on February 15, 2015. The purpose of the 2009 Plan and the 2014 Plan is to benefit stockholders by assisting the Company in attracting, retaining and providing incentives to key management employees and non-employee directors of, and non-employee consultants to, Cyalume Technologies Holdings, Inc. and its subsidiaries, and to align the interests of such employees, non-employee directors and non-employee consultants with those of stockholders. Accordingly, the 2009 Plan and the 2014 Plan both provide for the granting of Distribution Equivalent Rights, Incentive Stock Options, Non-Qualified Stock Options, Performance Share Awards, Performance Unit Awards, Restricted Stock Awards, Stock Appreciation Rights, Tandem Stock Appreciation Rights, Unrestricted Stock Awards or any combination of the foregoing, as may be best suited to the circumstances of the particular employee, director or consultant as provided therein. Under the 2009 Plan, the Company was authorized to issue up to 2,650,000 shares. Under the 2014 Plan, the Company is authorized to issue up to 10,000,000 shares. As of December 31, 2014, 1,150,082 shares were outstanding under the 2009 Plan. As of December 31, 2014, 2,676,582 shares were outstanding under the 2014 Plan. Awards under the plans can impose various service periods and other terms upon the awardee; however, the maximum term of options or similar instruments granted under the plans is ten years.

	Share-based awards are also issued that are not under either the 2009 Plan or the 2014 Plan. In September 2012, the Company awarded options to purchase the Company’s common stock to the Chief Operating Officer as part of his employment compensation. These options were not awarded under the 2009 Plan. Also in September 2012, the Company awarded options to purchase the Company’s common stock to East Shore Ventures, LLC as part of compensation for the Chief Executive Officer services provided by East Shore Ventures, LLC’s owner and employee. These options were also not awarded under the 2009 Plan. Because East Shore Ventures, LLC is not considered to be an employee under U.S. GAAP rules for accounting for share-based payments, the Company must estimate the fair value of these options every reporting period and adjust the related compensation cost accordingly.

	On November 21, 2014, options to purchase 350,000 shares of the Company’s common stock awarded to the Chief Operating Officer and options to purchase 1,036,104 shares of the Company’s common stock awarded to the Company’s Chief Executive Officer were canceled. These two awards were replaced with options to the Chief Operating Officer to purchase 1,504,767 shares of common stock and options to the Chief Executive Officer to purchase 5,015,891 shares of common stock. Both replacement awards were made outside of the Company’s 2014 Plan and were granted with a $0.09 exercise price. Both replacement awards are included in the section titled “Stock Option Awards” below.

	The Company accounted for the cancellation of the two officer awards and the concurrent grant of the replacement awards as a modification of the terms of the cancelled awards. The Company determined the incremental compensation cost by comparing the fair value of the replacement awards to the fair value of the cancelled awards on November 21, 2014. The replacement awards are subject to performance-based conditions that provide that each option shall not vest until the Company’s Term Loan, Real Estate Loan and Subordinated Term Loan have been re-financed such that the total cost of the new money does not exceed certain defined levels. Furthermore, the options provide for 100% vesting upon a sale of the Company at a defined minimum enterprise value.

	In accordance with ASC 718, compensation cost is recognized if it is probable that the performance condition will be achieved. The Company evaluated the probability of both the refinancing and the sale of the company being achieved at December 31, 2014 and determined that the probability threshold had not been met for either condition.

	The remaining unamortized compensation cost of approximately $0.4 million will be recognized on a straight-line basis over the remaining vesting period of the original canceled officer awards.

	During the years ended December 31, 2014 and 2013, total expense recorded for share-based compensation was approximately $394,000 and $773,000, respectively. The following presents how share-based expenses are included in our consolidated statements of comprehensive loss (in thousands):

			Year Ended December 31,
			2014			2013
	Cost of revenues		$	9		$	9
	Sales and marketing			38			44
	General and administrative			331			621
	Research and development			16			99
			$	394		$	773

	The Company does not currently possess any treasury shares; therefore any issuance of stock for any share-based compensation award is expected to be from new shares.

	Stock Option Awards

	The Black-Scholes pricing model is used to value stock options awarded as share-based compensation. The expected term of the options awarded under share-based compensation arrangements individually is estimated based on the estimated term of the award, the exercise price of the award, the estimated risk-free interest rate over the award’s estimated term, estimated annual dividend yield, and the estimated volatility of the price of our common stock over the award’s estimated term. Risk-free interest rate assumptions are based on U.S. Treasury securities issued with maturities similar to the expected terms of the awards. In September 2012, the Company began estimating the future volatility of the price of our common stock using historical daily prices of our common stock; before September 2012, since our common stock had insufficient trading history to estimate future price volatility, volatility was using historical data of another public company operating in our industry.

	The fair value of each award was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions for awards to employees and non-employees:


			2014				2013
	Expected term (years)			6.3 – 10.0				5.0 – 6.5
	Risk-free interest rate			1.83 – 2.31	%			1.10 – 1.70	%
	Estimated dividend yield			None				None
	Volatility			143.89 – 144.45	%			126.71 – 130.08	%

	Stock options awarded will generally vest in zero to 5 years. Options awarded to executive officers and other management often may be earned based on meeting Board-determined or CEO-determined performance goals unique to each award recipient and require continued employment over the vesting period. Options awarded to members of the Board of Directors typically vest on the grant date. Options awarded typically expire 10 years after the grant date.

	Stock option activity related to share-based compensation is summarized as follows:

		Shares			Weighted Average
		(in thousands)			Exercise Price
Outstanding at December 31, 2012			2,842		$	2.33
Granted ⁽¹⁾			708			1.79
Exercised			0			-
Forfeited			-415			2.02
Expired			-283			3.78
Outstanding at December 31, 2013			2,852			2.1
Granted ⁽²⁾			9,197			0.09
Exercised			0			-
Forfeited/Canceled			-1,520			1.52
Expired			-182			3.04
Outstanding at December 31, 2014			10,347		$	0.38
Exercisable at December 31, 2014			803		$	3.21

	-1	The weighted-average grant-date fair value of awards granted was $1.61.

	-2	The weighted-average grant-date fair value of awards granted was $0.09.

The following table summarizes information about stock options and warrants related to stock-based compensation that are vested or are expected to vest as of December 31, 2014:

										Options Outstanding					Options Exercisable
										Weighted
										Average			Weighted					Weighted
						Number				Remaining			Average		Number			Average
Range of						Outstanding				Contractual			Exercise		Exercisable			Exercise
Exercise Prices						(in thousands)				Term (Years)			Price		(in thousands)			Price
$	0		$	2			9,698				9.81		$	0.17		156		$	1.68
	2.01			4			524				4.96			3.33		522			3.33
	4.01			6			125				5.94			4.61		125			4.61
							10,347	-1			9.51		$	0.38		803	-2	$	3.21

	-1	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014.

	-2	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014. The weighted-average remaining contractual term for these options is 5.74 years as of December 31, 2014.

As of December 31, 2014, there was approximately $977,000 of unrecognized compensation cost related to nonvested option awards which is expected to be recognized over a weighted-average period of 7.72 years.

Restricted Stock

The Company values stock awards at the closing market price of the underlying shares on the trading day previous to the grant date, adjusted for expected forfeitures. There were no unvested restricted stock awards outstanding as of December 31, 2014.

Accumulated Other Comprehensive Loss

The ending accumulated balances for each item in accumulated other comprehensive loss are as follows (all amounts in thousands):

		Year Ended December 31,
		2014			2013
Foreign currency translation loss		$	-661		$	-218
Unrealized gain on cash flow hedges, net of taxes			0			0
		$	-661		$	-218

Changes in accumulated other comprehensive loss due to derivative instruments and hedging activities are as follows (all amounts in thousands):

Balance, December 31, 2012		$	-97
Unrealized gain on cash flow hedges, net of taxes of $(59) during 2013			97
Balance, December 31, 2013 and 2014		$	0

Changes in accumulated other comprehensive loss due to currency translation adjustments (all amounts in thousands):

Balance, December 31, 2012		$	-418
Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars			200
Balance, December 31, 2013			-218
Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars			-443
Balance, December 31, 2014		$	-661

Employee_Benefit_Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
EMPLOYEE BENEFIT PLANS		21	EMPLOYEE BENEFIT PLANS

	The CTI Employee Savings and Retirement Plan (the “ESRP”), is intended to be qualified under Section 401(k) of the Internal Revenue Code. Employees of CTI, CTS and CSP who have reached the age of 18 are eligible for participation on the first entry date after three months of service. Entry dates are the first day of January, April, July and October. Employees may defer receiving compensation up to the maximum amount permitted under the Internal Revenue Code. Matching contributions to the ESRP equal (i) 3% of employee compensation plus (ii) 50% of the next 2% of employee compensation. For the years ended December 31, 2014 and 2013, employer matching contributions were approximately $58,000 and $263,000, respectively.

	French law requires companies within France (such as CTSAS) to pay its workers a benefit, based on various factors, when an employee becomes 65 years old. The Company estimated the present value of such a liability for employees at CTSAS and approximately $78,000 and $79,000 has been recorded for this obligation as of December 31, 2014 and 2013, respectively.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2014
Risks and Uncertainties [Abstract]
CONCENTRATIONS	22	CONCENTRATIONS

	Sales Concentrations

	In 2014, approximately 41% of the Company’s revenue was received from two customers. In 2013, approximately 23% of the Company’s revenue was received from one customer.

	Geographic Concentrations

	The Company sells to customers located in the United States of America and in international markets. Revenues to customers outside the United States represent 52% and 32% of net revenues for the years ended December 31, 2014 and 2013, respectively. Revenues from customers in the United Kingdom represented 12% and 5% of our 2014 and 2013 revenues, respectively.

	CTSAS’ operations are our only operations outside the United States of America. CTSAS’ net assets were approximately $3,362,000 and $5,245,000 as of December 31, 2014 and 2013, respectively.

	Concentrations of Credit Risk Arising from Financial Instruments

	As of December 31, 2014, three customers combined represented approximately 49% of gross accounts receivable and royalty receivable, and no other customer owed more than 10% of gross accounts receivable. All of these accounts receivable were collected in full in the first quarter of 2015. As of December 31, 2013 three customers combined represented 47% of gross accounts receivable and no other customer owed more than 10% of gross accounts receivable.

	The Company maintains cash in several different financial institutions in amounts that typically exceed U.S. federally insured limits and in financial institutions in international jurisdictions where insurance is not provided. The Company has not experienced any losses in such accounts and the Company believes it is not exposed to significant credit risk. Beginning in 2013, insurance coverage reverted to $250,000 per depositor at each financial institution and the cash balances exceed federally-insured limits by approximately $1.5 million. As of December 31, 2014, cash in non-U.S. bank accounts that were not insured by a federal government totaled approximately $790,000.

Fair_Values_of_Assets_And_Liab

Fair Values of Assets And Liabilities	12 Months Ended
Fair Values of Assets And Liabilities	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FAIR VALUES OF ASSETS AND LIABILITIES	23	FAIR VALUES OF ASSETS AND LIABILITIES

	Assets and Liabilities Measured at Fair Value on a Recurring Basis

	Assets and liabilities itemized below were measured at fair value on a recurring basis at December 31, 2014:

			Level 1			Level 2			Level 3		Assets/
			Quoted			Significant			Significant		(Liabilities)
			Prices in			Other			Unobservable		At Fair
			Active			Observable			Inputs		Value
			Markets			Inputs
			for
			Identical
			Assets
	Warrants (see Note 19) ⁽¹⁾		$	0		$	0		$	-25	$	-25
			$	0		$	0		$	-25	$	-25

		-1	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.
		-1
	Assets and liabilities itemized below were measured at fair value on a recurring basis at December 31, 2013:

			Level 1			Level 2			Level 3		Assets/
			Quoted			Significant			Significant		(Liabilities)
			Prices in			Other			Unobservable		At Fair
			Active			Observable			Inputs		Value
			Markets			Inputs
			for
			Identical
			Assets
	Warrants (see Note 19) ⁽¹⁾		$	0		$	0		$	-6,373	$	-6,373
			$	0		$	0		$	-6,373	$	-6,373

		-1	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.

	The tables below presents reconciliations for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2014 and 2013:

			Year Ended December 31,
			2014			2013
	Warrants liability:
	Balance at the beginning of period		$	6,373		$	0
	Warrants amended in connection with refinancing			72			0
	Warrant exercise			-44			0
	Termination of common and preferred warrants			-1,524			0
	Change in fair value of warrants			-4,852			525
	Fair value recorded on the November 19, 2013 transaction date			0			5,848
	Balance at the end of period		$	25		$	6,373

	The Company has other financial instruments, such as cash, accounts receivable, due from related party, accounts payable, notes payable and a line of credit. The Company believes the carrying amounts of those assets and liabilities approximate their fair value since those carrying amounts have been estimated to approximate the exit price which would be received to sell these assets or pay to transfer these liabilities to a market participant. See Note 2 for a discussion of our accounting policy regarding fair value.

	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

	During the year ended December 31, 2014, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3):

		Cyalume Reporting Unit ⁽¹⁾			Loss Recognized			Fair Value
	Patents ⁽²⁾		Chemical Light		$	5,277		$	2,154
	Trade name ⁽³⁾		Chemical Light			4,303			667

	During the year ended December 31, 2013, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3):

		Cyalume Reporting Unit ⁽¹⁾			Loss Recognized			Fair Value
	Goodwill ⁽⁴⁾		CTS Training		$	168		$	0
	Patents ⁽²⁾		CTS Training			174			17
	Trade name ⁽³⁾		CTS Training			17			0
	Non-compete agreements ⁽⁵⁾		CTS Training			34			0
Customer Relationships		CTS Training			650			60

	-1	The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.). Specialty Products’ goodwill was not considered to be impaired and our Other reporting unit does not have a goodwill asset.

	-2	The fair value of the impaired patent asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach).

	-3	The fair value of the impaired trademarks and trade names asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).

	-4	The fair value of the impaired goodwill asset was determined calculating the excess of the fair value of the reporting unit over the fair values assigned to its assets and liabilities and utilized present value techniques utilizing each reporting unit’s forecasted after-tax cash flows.

	-5	The fair value of the impaired non-compete agreement asset was determined using the “comparative business valuation” method, which compares the present value of two streams of the reporting unit’s estimated future cash flows; one stream assuming the non-compete agreements are in place and the other stream assuming the agreements are not in place (an income approach).

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	12 Months Ended
Supplemental Disclosure of Cash Flow Information	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	24. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

	Cash Paid for Interest and Income Taxes (all amounts in thousands):

		Year Ended December 31,
		2014		2013
	Interest	$	592	$	1,693
	Income taxes		244		133

	Non-Cash Investing and Financing Activities (all amounts in thousands):

		Year Ended December 31,
		2014		2013
	Series A Convertible Preferred stock accrued dividend	$	509	$	55
	Series C Preferred stock accrued dividend		103		0
	Series A, Series B and Series C Preferred stock deemed dividends		4,921		4,000
	Adjustment to warrant liability upon warrant exercise		44		0
	Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP		241		0
	Issuance of 242,308 shares to related party		157		0
	Warrants liability recorded in connection with common and preferred warrants		0		5,607
	Litigation award payable accounted for as a receivable due from related party		0		134
	Amendment and adjustment to the fair value of warrants issued in conjunction with issuance of subordinated term loan recorded within warrant liability		0		241

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS		25	SUBSEQUENT EVENTS

	On February 19, 2015, an amendment was filed to the Company’s Fifth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, increasing the number of authorized shares of the Company’s common stock from 100,000,000 to 150,000,000. The Company’s 2014 Plan (see Note 20) was adopted by the Company’s stockholders on February 15, 2015.

Schedule_II_Valuation_and_Qual

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
Schedule II - Valuation and Qualifying Accounts	Dec. 31, 2014
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	Cyalume Technologies Holdings, Inc.
	Consolidated Financial Statement Schedule
	Schedule II – Valuation and Qualifying Accounts
	(in thousands)

	Description		Balance at		Charged		Deductions			Balance
			Beginning		to costs					at End of
			of Period		and					Period
					expenses
	Year ended December 31, 2013
	Allowance for Doubtful Accounts		$	155	$	2	$	-113	-1	$	44
	Deferred Tax Asset Valuation Allowance			3,874		2,048		—			5,922
	Year ended December 31, 2014
	Allowance for Doubtful Accounts		$	44	$	12	$	-34	-1	$	22
	Deferred Tax Asset Valuation Allowance			5,922		7,172		—			13,094

		-1	Write-offs and recoveries

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Foreign Operations	Foreign Operations

	The accounting records of our France-based subsidiary CTSAS are maintained in Euros, their local and functional currency. For consolidation, revenue and expense transactions are translated to U.S. dollars using the average exchange rate of the month in which the transaction took place. Assets and liabilities are translated to U.S. dollars using the exchange rate in effect as of the balance sheet date. Equity transactions are translated to U.S. dollars using the exchange rate in effect as of the date of the equity transaction. Translation gains and losses are reported as a component of accumulated other comprehensive income within stockholders’ equity. Gains and losses resulting from transactions which are denominated in other than the functional currency are reported as other income or loss in the statement of comprehensive income (loss) in the period the gain or loss occurred.

Comprehensive Loss	Comprehensive Loss

	Comprehensive loss accounts for changes in stockholders’ equity resulting from non-stockholder sources. All transactions that would cause comprehensive loss to differ from net loss have been recorded and disclosed and relate to (i) the translation of the accounting records of our France-based subsidiary CTSAS and (ii) the effective portion of activities designated as hedges for hedge accounting purposes.

Use of Estimates	Use of Estimates

	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates are used when accounting for certain items such as reserves for inventory, accounts receivable and deferred tax assets; assessing the carrying value of intangible assets including goodwill; determining the useful lives of property, plant and equipment and intangible assets; determining asset retirement obligations; and determining the fair value of contingent consideration. Estimates are based on historical experience, where applicable, and assumptions that are believed to be reasonable under the circumstances. Due to the inherent uncertainty involved with estimates, actual results may differ.

Accounts Receivable	Accounts Receivable

	Accounts receivable are recorded at the aggregate unpaid amount less any allowance for doubtful accounts. The allowance is based on historical bad debt experience and the specific identification of accounts deemed uncollectible. An account receivable’s delinquency status is determined based on its contractual terms. Interest is not charged on outstanding balances. Accounts are written off only when all methods of recovery have been exhausted. Credit risk is controlled through initial credit evaluations and approvals, credit limits, and monitoring procedures. Ongoing credit evaluations of customers are performed but do not require collateral to secure accounts receivable.

Inventories	Inventories

	Inventories are stated at the lower of cost (on a first-in first-out (“FIFO”) method) or net realizable value. The cost of inventory consists of raw material content, labor costs to produce the inventory and overhead costs incurred during production of the inventory. The Company periodically reviews the realizability of inventory. Provisions are recorded for potential obsolescence which requires management’s judgment. Conditions impacting the realizability of inventory could cause actual write-offs to be materially different than provisions for obsolescence.

Property, Plant and Equipment	Property, Plant and Equipment

	Property, plant and equipment are stated at cost. Depreciation is computed under the straight-line method over the estimated useful lives of four to eight years for equipment and 30 years for buildings and improvements.

	Property, plant and equipment assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Such reviews are based on a comparison of the asset’s undiscounted cash flows to the recorded carrying value for the asset. Impairment charges, if any, are recorded in the period in which the impairment is determined.

Goodwill	Goodwill

	Goodwill is deemed to have an indefinite life and accordingly, is not subject to amortization. Goodwill is subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon its estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined.

	The Company performs a traditional two-step process for assessing goodwill for impairment annually. The first step of the two-step process requires a comparison of estimated fair value for each reporting unit versus the carrying or book value. If the carrying value exceeds fair value, further analysis (step 2 of the two-step process) is required to determine the amount, if any, that goodwill is impaired. Fair value is determined using a discounted cash flow analysis.

Intangible Assets	Intangible Assets

	Intangible assets include developed technologies and patents, customer relationships, non-compete agreements, trademarks and trade names, all of which are amortized over their estimated useful lives. The carrying amounts of amortizing intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable.

	Costs incurred to register new patents or defend existing patents are capitalized, while costs to renew or extend the term of intangible assets are expensed when incurred. Costs incurred with third parties that are related to internally developing or successfully defending an intangible asset are capitalized as part of the intangible asset developed or defended and amortized over that asset’s remaining useful life. Such costs with third parties related to patent or trademark applications that are ultimately rejected by the relevant government authority are expensed upon rejection. The useful lives used for amortization of intangible assets are as follows:

			Useful lives
	Patents and developed technologies			-1
	Purchased customer relationships			9 – 13 years
	Trademarks and trade names			-2
	Non-compete agreements			5 years

		-1	Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 years thereafter. Amortization on patent costs begins when the relevant government authority approves the related patent. Patents that have been recorded as of December 31, 2014 are expected to expire by 2034. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on patents of approximately $5.3 million was recorded during 2014 (see Note 3).

		-2	Trademarks and trade names of CTI are deemed to have a useful life of 15 years. CTI’s trademarks and trade names are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on trade names of approximately $4.3 million was recorded during 2014 (see Note 3).

Debt Issuance and Deferred Financing Costs	Debt Issuance and Deferred Financing Costs

	Costs paid to lenders to obtain financing are presented as discounts on the related debt and are amortized to interest expense over the term of the related financing, using the effective interest method (unless the financing is a line of credit, in which case the straight-line method is used). Such costs paid to third parties are presented as assets and are amortized to interest expense in the same manner as costs paid to lenders.

Derivatives	Derivatives

	Derivatives are recorded at their fair value as of the balance sheet date. If a derivative qualifies for “hedge accounting” under U.S. GAAP and has been designated as a hedge by us, then the “effectively hedged” portion is recorded, as defined by U.S. GAAP, of changes in such derivatives’ fair value in accumulated other comprehensive loss, which is a component of our stockholders’ equity. The Company records (i) ineffectively hedged portions of such changes in fair value or (ii) changes in the fair value of derivatives not designated as a hedge in our consolidated statement of comprehensive loss in the period the change occurred. On the consolidated statement of cash flows, cash flows from derivative instruments accounted for as cash flow hedges are classified in the same category as the cash flows from the items being hedged.

Warrants Liability	Warrants Liability

	The Company uses fair values as determined by significant unobservable inputs. These estimated values are significant inputs into the Monte Carlo simulation method and the Black Scholes pricing model used to calculate the estimated fair value of common warrants and preferred warrants potentially settleable in cash, which are recorded as warrants liability. The estimated fair value of the common warrants and the preferred warrants are determined at each balance sheet date and the change in the estimated fair value of the warrants is reflected within the Company’s statements of comprehensive loss. Certain common and preferred warrants were terminated on July 30, 2014 (see Note 19).

Revenue Recognition	Revenue Recognition

	Revenue from the sale of products or the providing of services is recognized when the earnings process is complete, the amount of recognizable revenue can be determined, the risks and rewards of ownership have transferred to the customer and collectability is reasonably assured. Depending on the terms of the individual sales arrangement with our customer, product sales are recognized at either the shipping point or upon receipt by the customer. Costs and related expenses to manufacture the products are recorded as costs of goods sold when the related revenue is recognized. Additionally, if the right of return is granted to the buyer in a product sale, revenue is deferred until enough historical customer data is available to reasonably estimate returns and related costs.

	Two significant contracts provide for the sale of indefinite quantities of products at fixed per unit prices, subject to adjustment for certain economic factors. Revenue under these contracts is recognized when products ordered under the contracts are received by the customer. Whenever costs change, the pricing under these contracts is reviewed to determine whether they require the sale of products at a loss. To date, there are no loss contracts which would require the accrual of future losses in the current financial statements.

	Research and development services are provided for customers for which the Company earns payments that are contingent upon achieving a specific result (“milestones”). Upon achieving such milestones, revenue is recognized provided that the payment is (i) related to past performance, (ii) reasonable relative to all of the deliverables and payment terms within the arrangement with our customer, and (iii) nonrefundable.

Taxes Collected from Customers	Taxes Collected from Customers

	Sales taxes collected from customers are not considered revenue and are included in accounts payable and accrued expenses until remitted to the taxing authorities.

Shipping and Handling Costs	Shipping and Handling Costs

	Outbound shipping and handling costs are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). These costs were approximately $358,000 and $423,000 for the years ended December 31, 2014 and 2013, respectively.

Advertising Costs	Advertising Costs

	Advertising costs are expensed as incurred and are included in sales and marketing expenses in the accompanying consolidated statements of comprehensive income (loss). Advertising expense was $151,000 and $215,000 for the years ended December 31, 2014 and 2013, respectively.

Stock-Based Compensation	Stock-Based Compensation

	Stock-based compensation is incurred related to awards of common stock, restricted common stock and options to employees and non-employees. Those awards are measured at their fair value on the date the award is granted and are recognized in our consolidated financial statements over the period the grantee is required to provide services in exchange for the award. When recognized as an expense, the fair value of the award, less estimated forfeitures, is recognized on a straight-line basis over the award service period; if there is no such service period, then the entire fair value of the award is recognized as expense on the grant date.

Research and Development	Research and Development

	The Company has research and development groups with full-time chemists and engineers at both the West Springfield and Bound Brook facilities. The research and development groups are focused on maintaining quality of existing products, developing improvements to existing products, and developing new technologies and products with viable commercial applications. Research and development costs are expensed as incurred.

Income Taxes	Income Taxes

	Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are recognized when, based upon available evidence, realization of the assets is more likely than not.

	In assessing the realization of long-term deferred income tax assets, it is considered whether it is more likely than not that the deferred income tax assets will be realized. The realization of deferred income tax assets depends upon future taxable income in years before net operating loss carryforwards expire. The recoverability of deferred income tax assets is evaluated on a quarterly basis. If the Company determines that it is more likely than not that deferred income tax assets will not be recovered, a valuation allowance is established against some or all deferred income tax assets.

	When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefit associated with tax positions taken that exceeds the amount measured as described above, if such a position existed, would be reflected as a liability for unrecognized tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. There were no such positions as of December 31, 2014 or 2013.

	Interest on tax deficiencies is classified as interest expense and income tax penalties are classified as other expense.

	In February 2012, an IRS audit was completed of the Company’s tax returns for the years 2008 and 2009. There were no adjustments to those tax returns. Tax returns filed for the years 2010, 2011, 2012 and 2013 are still open for audit and the 2013 tax return has been selected for examination by the IRS. The tax return for 2014 is expected to be filed under a filing extension prior to September 15, 2015.

Net Loss per Common Share	Net Loss per Common Share

	Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted loss per common share is computed by dividing net loss by the weighted average number of common shares and dilutive potential common share equivalents then outstanding. Potential common share equivalents consist of (i) shares issuable upon the exercise of warrants and options (using the “treasury stock” method), (ii) unvested restricted stock awards (using the “treasury stock” method) and (iii) shares issuable upon conversion of convertible notes and convertible preferred stock using the “if-converted” method.

			(in thousands, except shares and per share information)
			Year Ended December 31,
			2014		2013
	Numerator (in thousands):
	Net loss		$	-7,716	$	-15,653
	Series A convertible preferred stock dividends			-509		-55
	Series C preferred stock dividends			-103		0
	Series A deemed dividend			-2,422		-5,553
	Series B deemed dividend			-1,098		0
	Series C deemed dividend			-1,401		0
	Loss available to common stockholders – basic and diluted		$	-13,249	$	-21,261

	Denominator:
	Weighted average shares outstanding – basic and diluted			21,294,432		20,714,531

	Loss per common share:
	Basic and diluted loss per common share		$	-0.62	$	-1.03

	The following potentially dilutive common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was antidilutive for each of the periods presented:

			Year Ended December 31,
			2014		2013
	Options			10,347,322		2,852,186
	Series A convertible preferred stock			33,401,765		6,153,850
	Series B convertible preferred stock			35,713,147		0
	Amended related party note			3,997,074		1,538,450
	Convertible notes payable			2,666,667		2,666,667
	Warrants			455,514		528,523
	Restricted stock awards			0		34,266

	A preferred warrant convertible into 123,077 shares of Series A preferred stock was only exercisable if 2014 earnings fell below a certain threshold. The 123,077 shares of Series A preferred stock would have been convertible into 6,153,850 shares of the Company’s common stock. The preferred warrant was terminated on July 30, 2014. The underlying 6,153,850 common shares issuable upon conversion of the Series A preferred stock relating to the preferred warrant were not included in the computation of diluted loss per common share for the years ended December 31, 2014 and 2013.

	In connection with the issuance of the Company's Series A preferred stock, warrants to purchase a total of 528,523 shares of the Company's common stock were issued. If the preferred warrant became exercisable, the warrant shares pursuant to the warrants would have been increased by 174,404. The preferred warrant was terminated on July 30, 2014. The 174,404 contingently issuable warrant shares were not included in the computation of diluted loss per common share for the years ended December 31, 2014 and 2013.

Fair Value	Fair Value

	Under U.S. GAAP, the Company is required to record certain financial assets and liabilities at fair value and may choose to record other financial assets and financial liabilities at fair value as well. Also under U.S. GAAP, the Company is required to record nonfinancial assets and liabilities at fair value due to events that may or may not recur in the future, such as an impairment event. When required to record such assets and liabilities at fair value, that fair value is estimated using an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. That fair value is determined based on significant inputs contained in a fair value hierarchy as follows:

		Level 1	Quoted prices for identical assets or liabilities in active markets to which we have access at the measurement date.

		Level 2	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

		Level 3	Unobservable inputs for the asset or liability.

	The determination of where assets and liabilities fall within this hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

	There are three general valuation techniques that may be used to measure fair value, as described below:

	Market Approach	Uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Prices may be indicated by pricing guides, sale transactions, market trades, or other sources.

	Cost Approach	Based on the amount that currently would be required to replace the service capacity of an asset (replacement cost).

	Income Approach	Uses valuation techniques to convert future amounts to a single present amount based on current market expectations about the future amounts (includes present value techniques and option-pricing models). Net present value is an income approach where a stream of expected cash flows is discounted at an appropriate market interest rate.

Recent Accounting Pronouncements	Recent Accounting Pronouncements

	The following are recent accounting pronouncements that have affected our consolidated financial statements or may affect them in the future.

	In July 2013, the FASB issued Accounting Standards Update (“ASU”) 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carry-forward, a Similar Tax Loss, or a Tax Credit Carry-forward Exists (“ASU 2013-11”) to clarify that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss (“NOL”) carry-forward, a similar tax loss, or a tax credit carry-forward, with some allowed exceptions. ASU 2013-11 does not impose any new recurring disclosure requirements because it does not affect the recognition or measurement of uncertain tax positions. ASU 2013-11 is effective for fiscal years beginning after December 15, 2013. The adoption of ASU 2013-11 did not have a material impact on our financial position or results of operations.

	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 0214-09”). ASU 2014-09 states that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new standard will be effective for annual and interim periods beginning on or after December 15, 2016, and will be effective for the Company beginning on January 1, 2017. Early adoption is not permitted. The Company is currently evaluating the method of adoption and the potential impact the update may have on our financial position and results of operations.

	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements – Going Concern (Topic 915): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”). ASU 2014-15 states that in connection with preparing financial statements for each annual and interim reporting period, an entity’s management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). ASU 2014-15 will be effective for annual and interim periods beginning on or after December 15, 2016, and will be effective for the Company beginning on January 1, 2017. Early adoption is permitted. The Company is currently evaluating the impact, if any, of the adoption of this update.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule Of Useful Lives For Amortization Of Intangible Assets	The useful lives used for amortization of intangible assets are as follows:

			Useful lives
	Patents and developed technologies			-1
	Purchased customer relationships			9 – 13 years
	Trademarks and trade names			-2
	Non-compete agreements			5 years

		-1	Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patents’ legal lives begin when the related patent application is filed with the relevant government authority and ends 20 years thereafter. Amortization on patent costs begins when the relevant government authority approves the related patent. Patents that have been recorded as of December 31, 2014 are expected to expire by 2034. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on patents of approximately $5.3 million was recorded during 2014 (see Note 3).

		-2	Trademarks and trade names of CTI are deemed to have a useful life of 15 years. CTI’s trademarks and trade names are reviewed for impairment whenever events or changes in circumstances indicate that those carrying amounts may not be recoverable. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on trade names of approximately $4.3 million was recorded during 2014 (see Note 3).

Net Income Per Common Share	Potential common share equivalents consist of (i) shares issuable upon the exercise of warrants and options (using the “treasury stock” method), (ii) unvested restricted stock awards (using the “treasury stock” method) and (iii) shares issuable upon conversion of convertible notes and convertible preferred stock using the “if-converted” method.

			(in thousands, except shares and per share information)
			Year Ended December 31,
			2014		2013
	Numerator (in thousands):
	Net loss		$	-7,716	$	-15,653
	Series A convertible preferred stock dividends			-509		-55
	Series C preferred stock dividends			-103		0
	Series A deemed dividend			-2,422		-5,553
	Series B deemed dividend			-1,098		0
	Series C deemed dividend			-1,401		0
	Loss available to common stockholders – basic and diluted		$	-13,249	$	-21,261

	Denominator:
	Weighted average shares outstanding – basic and diluted			21,294,432		20,714,531

	Loss per common share:
	Basic and diluted loss per common share		$	-0.62	$	-1.03

Common Shares Issuable upon Vesting or Exercise of Convertible Securities	The following potentially dilutive common share equivalents were excluded from the calculation of diluted net loss per common share because their effect was antidilutive for each of the periods presented:

			Year Ended December 31,
			2014		2013
	Options			10,347,322		2,852,186
	Series A convertible preferred stock			33,401,765		6,153,850
	Series B convertible preferred stock			35,713,147		0
	Amended related party note			3,997,074		1,538,450
	Convertible notes payable			2,666,667		2,666,667
	Warrants			455,514		528,523
	Restricted stock awards			0		34,266

Inventories_Tables

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories, net consist of the following (all amounts in thousands):

		2014		2013
	Raw materials	$	4,777	$	6,535
	Work-in-process		1,546		2,185
	Finished goods		1,503		2,062
		$	7,826	$	10,782

Prepaid_Expenses_And_Other_Cur1

Prepaid Expenses And Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses And Other Current Assets (Tables)	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (all amounts in thousands):

		2014		2013
	Value added taxes receivable	$	30	$	17
	Prepaid expenses		495		312
	Debt issuance costs, current portion		21		53
	Other		102		81
		$	648	$	463

Property_Plant_And_Equipment_T

Property, Plant And Equipment (Tables)	12 Months Ended
Property, Plant And Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment consist of the following (all amounts in thousands):

		2014		2013
	Land	$	1,267	$	1,285
	Building and improvements		3,564		3,332
	Machinery and equipment		8,408		8,300
	Leasehold improvements		275		266
	Furniture and fixtures		131		122
	Software		132		59
			13,777		13,364
	Less: accumulated depreciation and amortization		-6,657		-5,363
		$	7,120	$	8,001

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Dec. 31, 2014
Goodwill, Impaired [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill consist of the following (all amounts in thousands):

			CTI/CTSAS/CTS		CSP		Total
			Chemical Light				Consolidated
							Goodwill
	Balance on December 31, 2012		$	5,182	$	2,978	$	8,160
	Impairment loss (see Notes 3 and 23)			-168		0		-168
	Balance on December 31, 2013 ⁽¹⁾		$	5,014	$	2,978	$	7,992
	Impairment loss (see Notes 3 and 23)			0		0		0
	Balance on December 31, 2014 ⁽²⁾		$	5,014	$	2,978	$	7,992

		(1)(2)	Gross amount of goodwill was approximately $67.7 million as of December 31, 2014 and 2013. Accumulated impairment losses were approximately $59.7 million as of December 31, 2014 and 2013.

Other_Intangible_Assets_Tables

Other Intangible Assets (Tables)	12 Months Ended
Other Intangible Assets (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets as of December 31, 2014 consist of the following (all amounts in thousands):

					Accumulated
			Cost		Amortization		Net Book Value
	Developed technologies, including patents ⁽¹⁾		$	8,736	$	6,582	$	2,154
	Trademarks and trade names ⁽⁴⁾			1,068		401		667
	Purchased customer relationships ⁽²⁾			8,562		4,858		3,704
	Non-compete agreements ⁽³⁾			160		107		53
	Website development costs			16		3		13
			$	18,542	$	11,951	$	6,591

	Intangible assets as of December 31, 2013 consist of the following (all amounts in thousands):

					Accumulated
			Cost		Amortization		Net Book Value
	Developed technologies, including patents ⁽¹⁾		$	13,853	$	5,720	$	8,133
	Trademarks and trade names ⁽⁴⁾			5,365		119		5,246
	Purchased customer relationships ⁽²⁾			8,812		4,336		4,476
	Non-compete agreements ⁽³⁾			160		75		85
	Website development costs			8		0		8
			$	28,198	$	10,250	$	17,948

		-1	Includes a patent obtained in the acquisition of CSP with a cost of $50,000 that is expected to be fully amortized in August 2026. Patents obtained in the acquisition of CTS with an initial cost of $410,000 and a December 31, 2012 gross value of approximately $238,000 were impaired by approximately $174,000 during 2013 (see Note 3 Impairment Charges) and the $17,000 of CTS patents remaining after the impairment was transferred to CTI in 2014. The CTI patents were impaired by approximately $5.3 million during 2014 (see Note 3 Impairment Charges).
		-2	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. Customer relationships obtained in the acquisition of CTS with a cost of $840,000 was impaired by approximately $650,000 during 2013 (see Note 3 Impairment Charges) and the $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.
		-3	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016. A non-compete agreement obtained in the acquisition of CTS with an initial cost of $140,000 was impaired by approximately $34,000 in 2013 (see Note 3 Impairment Charges).
		-4	Includes CTS trade names which were impaired by approximately $17,000 in 2013 (see Note 3 Impairment Charges). Includes CTI trademarks and trade names which were impaired by approximately $4.3 million during 2014 (see Note 3 Impairment Charges).

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The future amortization expense relating to finite-lived intangible assets for the next five years and beyond is estimated at December 31, 2014 to be (all amounts in thousands):

	Year Ending December 31,
	2015		$	957
	2016			947
	2017			922
	2018			910
	2019			841
	Thereafter			1,894
			$	6,471

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
Accrued Expenses (Tables)	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued expenses consist of the following (all amounts in thousands):

			2014		2013
	Payroll-related ⁽¹⁾		$	834	$	1,145
	Interest payable			550		301
	Subordinated term loan exit fee			285		30
	Professional fees			87		26
	Franchise and sales tax payable			50		51
	Other			884		348
	Related party payable – Selway Capital, LLC ⁽²⁾			0		158
			$	2,690	$	2,059

		-1	Accrued payroll-related costs as of December 31, 2014 include approximately $141,000 of accrued severance costs. Accrued payroll-related costs as of December 31, 2013 include approximately $534,000 of accrued severance costs.
		-2	See Note 13 for a description of the agreement with Selway Capital, LLC.

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
Notes Payable (Tables)	Dec. 31, 2014
Notes Payable [Abstract]
Schedule of Debt	Outstanding notes payable consist of (all amounts in thousands):

		2014		2013
	Senior Debt - Term Loan	$	4,239	$	6,023
	Senior Debt - Real Estate Loan		1,551		1,679
	Subordinated Term Loan		9,676		8,659
	Promissory Note Payable		860		1,075
	Total		16,326		17,436
	Less: Unamortized debt discount		-337		-542
	Less: Current portion of notes payable, including current portion of unamortized debt discount		-5,775		-1,925
	Notes payable, net of current portion	$	10,214	$	14,969

Schedule Of Carrying Value Of The Subordinated Term Loan	The carrying value of the Subordinated Term Loan is as follows (all amounts in thousands):

		2014		2013
	Principal amount of loan	$	9,676	$	8,659
	Less: unamortized debt discount		-285		-424
		$	9,391	$	8,235

Schedule Of Interest Costs Of The Subordinated Term Loan	Interest costs for the Subordinated Term Loan are as follows (all amounts in thousands):

		2014		2013
	Contractual interest coupon rate	$	1,153	$	949
	Amortization of related debt discount and debt issuance costs		221		486
	Total interest expense recognized	$	1,374	$	1,435

Schedule of Contractual Obligation, Fiscal Year Maturity	As of December 31, 2014, future minimum payments due for notes payable (excluding the related party note payable discussed in Note 13) for each of the five succeeding years and beyond are as follows (all amounts in thousands):

	Year Ending December 31,
	2015	$	6,005
	2016		9,891
	2017		215
	2018		215
	2019		0
	Thereafter		0
		$	16,326

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign	The components of income (loss) before income taxes are as follows:

			Year Ended December 31,
			2014		2013
	Domestic		$	-7,569	$	-18,866
	Foreign			1,091		175
			$	-6,478	$	-18,691

Schedule of Components of Income Tax Expense (Benefit)	Provision for (benefit from) income taxes consisted of the following (all amounts in thousands):

			Year Ended December 31,
			2014		2013
	Current:
	Federal		$	223	$	0
	State			156		160
	Foreign			443		130
	Deferred:
	Federal			2,008		-2,678
	State			-1,513		-595
	Foreign			-79		-55
	Provision for (benefit from) income taxes		$	1,238	$	-3,038

Schedule of Deferred Tax Assets and Liabilities	Deferred income tax assets and liabilities consist of the following (all amounts in thousands):

			December 31, 2014				December 31, 2013
			Current		Non-current		Current		Non-current
	Deferred tax assets:
	Federal		$	2,699	$	11,857	$	6,329	$	7,230
	State			777		1,426		886		868
	Foreign			0		0		34		20
	Less: valuation allowance			-2,741		-10,353		-2,747		-3,175
				735		2,930		4,502		4,943
	Deferred tax liabilities:
	Federal			-805		-2,103		-477		-6,615
	State			-219		-538		-124		-1,697
	Foreign			-16		-414		-54		-478
				-1,040		-3,055		-655		-8,790
	Deferred tax assets (liabilities)		$	-305	$	-125	$	3,847	$	-3,847

	Principal components of our net liability representing deferred income tax balances are as follows (all amounts in thousands):

			Year Ended December 31,
			2014		2013
	Intangible assets		$	178	$	-3,778
	Property, plant and equipment			-661		-740
	U.S. loss carryforwards and tax credits, net ⁽¹⁾			10,151		8,974
	Subsidiary income ⁽²⁾			-764		-1,671
	Stock-based compensation expense			1,142		968
	Reserves, accruals and other			1,664		1,292
	State deferred tax asset			954		0
	Change in warrants fair value			0		877
	Valuation allowance			-13,094		-5,922
			$	-430	$	0

		-1	The Company had federal net operating loss carryforwards amounting to approximately $7.9 million and $13.3 million at December 31, 2014 and 2013, respectively. The net operating loss carryforward at December 31, 2014 expires in fiscal years 2026 through 2034. Internal Revenue Code Section 382 limits utilization of these losses to approximately $0.8 million per year. It is possible that future changes in ownership could result in changes to the amounts allowed by IRC Section 382. State net operating loss carryforwards amounted to approximately $10.3 million and $9.9 million as of December 31, 2014 and 2013, respectively.

		-2	A deferred tax liability has been recorded for income taxes which may become payable upon distribution of earnings of CTSAS, our French subsidiary. The estimated amount of tax that might be payable with regard to any distribution for foreign subsidiary earnings is reported net of foreign taxes paid, which are creditable against our domestic tax liability. The Company does not permanently reinvest foreign subsidiary earnings. The Company continually evaluates this assertion; if the Company’s foreign business needs change, so may this assertion.

Schedule of Effective Income Tax Rate Reconciliation	Income taxes computed using the federal statutory income tax rate differs from our effective tax rate primarily due to the following (all amounts in thousands):

			Year Ended December 31,
			2014		2013
	Provision for federal income taxes expected at 34% statutory rate		$	-2,201	$	-6,355
	Increase (reduction) resulting from:
	Tax on global activities, net of foreign tax credits			-2,842		2
	State income taxes, less federal income tax benefit			-895		-287
	Loss on debt extinguishment			179		728
	Change in valuation allowance			7,172		3,507
	Change in fair value of warrants			-1,518		0
	Goodwill impairment loss			0		57
	Prior year true up			1,008		-715
	Other			335		25
	Provision for (benefit) from income taxes		$	1,238	$	-3,038

Asset_Retirement_Obligation_Ta

Asset Retirement Obligation (Tables)	12 Months Ended
Asset Retirement Obligation (Tables)	Dec. 31, 2014
Asset Retirement Obligation Disclosure [Abstract]
Schedule Of Significant Assumptions Used To Estimate The Obligation	The Company has an obligation to remediate certain known occurrences of asbestos at our manufacturing facility in West Springfield, Massachusetts. The significant assumptions used to estimate the obligation are:

	Annual inflation rate			5.54	%
	Credit-adjusted risk-free rate			5.37	%
	Initial estimated remediation costs (undiscounted and not adjusted for inflation)			$200,000 ($41,000 paid in 2007)
	Estimated remediation completion date			19-Dec-38
	Estimated remediation cost on December 19, 2038		$	720,000

Schedule of Change in Asset Retirement Obligation	The following is a reconciliation of the beginning and ending aggregate carrying amounts of the asset retirement obligation (all amounts in thousands):

			Year Ended December 31,
			2014			2013
	Balance, beginning		$	194		$	184
	Accretion expense			10			10
	Balance, ending		$	204	-1	$	194

		-1	The difference between the $204,000 liability as of December 31, 2014 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2014 and December 19, 2038.

Commitments_And_Contingencies_

Commitments And Contingencies (Tables)	12 Months Ended
Commitments And Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum lease payments under non-cancelable lease obligations at December 31, 2014 are as follows (all amounts in thousands):

	Year Ending December 31,
	2015	$	595
	2016		480
	2017		242
	2018		59
	2019		0
	Thereafter		0
		$	1,376

Preferred_Stock_Tables

Preferred Stock (Tables)	12 Months Ended
Preferred Stock (Tables)	Dec. 31, 2014
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Change In The Fair Value Of The Warrants Liability	The change in the fair value of the warrants liability during the year ended December 31, 2014 is as follows (amounts in thousands):

								Subordinated
								Term Loan
		Common		Preferred				Warrants (see)		Total Warrant
		Warrant		Warrant		JFC Warrant		Note 12)		Liability
	Warrant liability at December 31, 2013	$	4,081	$	1,997	$	54	$	241	$	6,373
	Warrants amended in connection with refinancing		0		0		0		72		72
	Warrant exercise		0		0		-44		0		-44
	Change in fair value of warrants		-3,331		-1,223		-10		-288		-4,852
	Termination of Common and Preferred Warrants		-750		-774		0		0		-1,524
	Warrant liability at December 31, 2014	$	0	$	0	$	0	$	25	$	25

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity Note, Warrants or Rights	Warrants to purchase the Company’s common stock were outstanding as follows as of December 31, 2014:

			Number of			Number of
			Shares			Shares
			Exercisable			Exercisable
			Under			Under			Exercise
	Warrant Holder		Warrant			Warrant			Price			Expiration Date
	Granite Creek FlexCap I, L.P.			267,950			267,950		$	0.01		19-Nov-23
	Patriot Capital II, L.P.			187,564			187,564		$	0.01		19-Nov-23

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following presents how share-based expenses are included in our consolidated statements of comprehensive loss (in thousands):

			Year Ended December 31,
			2014			2013
	Cost of revenues		$	9		$	9
	Sales and marketing			38			44
	General and administrative			331			621
	Research and development			16			99
			$	394		$	773

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair value of each award was estimated on the date of grant using the Black-Scholes pricing model with the following assumptions for awards to employees and non-employees:


			2014				2013
	Expected term (years)			6.3 – 10.0				5.0 – 6.5
	Risk-free interest rate			1.83 – 2.31	%			1.10 – 1.70	%
	Estimated dividend yield			None				None
	Volatility			143.89 – 144.45	%			126.71 – 130.08	%

Schedule of Share-based Compensation, Stock Options, Activity	Stock option activity related to share-based compensation is summarized as follows:

			Shares			Weighted Average
			(in thousands)			Exercise Price
	Outstanding at December 31, 2012			2,842		$	2.33
	Granted ⁽¹⁾			708			1.79
	Exercised			0			-
	Forfeited			-415			2.02
	Expired			-283			3.78
	Outstanding at December 31, 2013			2,852			2.1
	Granted ⁽²⁾			9,197			0.09
	Exercised			0			-
	Forfeited/Canceled			-1,520			1.52
	Expired			-182			3.04
	Outstanding at December 31, 2014			10,347		$	0.38
	Exercisable at December 31, 2014			803		$	3.21

		-1	The weighted-average grant-date fair value of awards granted was $1.61.

		-2	The weighted-average grant-date fair value of awards granted was $0.09.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable	The following table summarizes information about stock options and warrants related to stock-based compensation that are vested or are expected to vest as of December 31, 2014:

											Options Outstanding				Options Exercisable
											Weighted
											Average		Weighted					Weighted
							Number				Remaining		Average		Number			Average
	Range of						Outstanding				Contractual		Exercise		Exercisable			Exercise
	Exercise Prices						(in thousands)				Term (Years)		Price		(in thousands)			Price
	$	0		$	2			9,698				9.81	$	0.17		156		$	1.68
		2.01			4			524				4.96		3.33		522			3.33
		4.01			6			125				5.94		4.61		125			4.61
								10,347	-1			9.51	$	0.38		803	-2	$	3.21

		-1	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014.

		-2	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014. The weighted-average remaining contractual term for these options is 5.74 years as of December 31, 2014.

Schedule of Accumulated Other Comprehensive Income (Loss)	The ending accumulated balances for each item in accumulated other comprehensive loss are as follows (all amounts in thousands):

			Year Ended December 31,
			2014			2013
	Foreign currency translation loss		$	-661		$	-218
	Unrealized gain on cash flow hedges, net of taxes			0			0
			$	-661		$	-218

Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive loss due to derivative instruments and hedging activities are as follows (all amounts in thousands):

	Balance, December 31, 2012		$	-97
	Unrealized gain on cash flow hedges, net of taxes of $(59) during 2013			97
	Balance, December 31, 2013 and 2014		$	0

Schedule Of Foreign Currency Translation Adjustment In Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive loss due to currency translation adjustments (all amounts in thousands):

	Balance, December 31, 2012		$	-418
	Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars			200
	Balance, December 31, 2013			-218
	Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars			-443
	Balance, December 31, 2014		$	-661

Fair_Values_of_Assets_And_Liab1

Fair Values of Assets And Liabilities (Tables)	12 Months Ended
Fair Values of Assets And Liabilities (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Assets and Liabilities Measured at Fair Value on Recurring Basis	Assets and liabilities itemized below were measured at fair value on a recurring basis at December 31, 2014:

			Level 1			Level 2			Level 3		Assets/
			Quoted			Significant			Significant		(Liabilities)
			Prices in			Other			Unobservable		At Fair
			Active			Observable			Inputs		Value
			Markets			Inputs
			for
			Identical
			Assets
	Warrants (see Note 19) ⁽¹⁾		$	0		$	0		$	-25	$	-25
			$	0		$	0		$	-25	$	-25

		-1	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.
		-1
	Assets and liabilities itemized below were measured at fair value on a recurring basis at December 31, 2013:

			Level 1			Level 2			Level 3		Assets/
			Quoted			Significant			Significant		(Liabilities)
			Prices in			Other			Unobservable		At Fair
			Active			Observable			Inputs		Value
			Markets			Inputs
			for
			Identical
			Assets
	Warrants (see Note 19) ⁽¹⁾		$	0		$	0		$	-6,373	$	-6,373
			$	0		$	0		$	-6,373	$	-6,373

		-1	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.

Reconciliation of Contingent Consideration Liability Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs	The tables below presents reconciliations for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the years ended December 31, 2014 and 2013:

			Year Ended December 31,
			2014			2013
	Warrants liability:
	Balance at the beginning of period		$	6,373		$	0
	Warrants amended in connection with refinancing			72			0
	Warrant exercise			-44			0
	Termination of common and preferred warrants			-1,524			0
	Change in fair value of warrants			-4,852			525
	Fair value recorded on the November 19, 2013 transaction date			0			5,848
	Balance at the end of period		$	25		$	6,373

Assets and Liabilities Measured at Fair Value on Non-Recurring Basis	Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

	During the year ended December 31, 2014, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3):

		Cyalume Reporting Unit ⁽¹⁾			Loss Recognized			Fair Value
	Patents ⁽²⁾		Chemical Light		$	5,277		$	2,154
	Trade name ⁽³⁾		Chemical Light			4,303			667

	During the year ended December 31, 2013, the following assets, all of which are Level 3 assets, were identified as impaired and were adjusted to their fair values (in thousands of dollars) (see also Note 3):

		Cyalume Reporting Unit ⁽¹⁾			Loss Recognized			Fair Value
	Goodwill ⁽⁴⁾		CTS Training		$	168		$	0
	Patents ⁽²⁾		CTS Training			174			17
	Trade name ⁽³⁾		CTS Training			17			0
	Non-compete agreements ⁽⁵⁾		CTS Training			34			0
	Customer Relationships		CTS Training			650			60

		-1	The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.). Specialty Products’ goodwill was not considered to be impaired and our Other reporting unit does not have a goodwill asset.

		-2	The fair value of the impaired patent asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach).

		-3	The fair value of the impaired trademarks and trade names asset was determined using the “relief from royalty” method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).

		-4	The fair value of the impaired goodwill asset was determined calculating the excess of the fair value of the reporting unit over the fair values assigned to its assets and liabilities and utilized present value techniques utilizing each reporting unit’s forecasted after-tax cash flows.

		-5	The fair value of the impaired non-compete agreement asset was determined using the “comparative business valuation” method, which compares the present value of two streams of the reporting unit’s estimated future cash flows; one stream assuming the non-compete agreements are in place and the other stream assuming the agreements are not in place (an income approach).

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Tables)	12 Months Ended
Supplemental Disclosure of Cash Flow Information (Tables)	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash Paid for Interest and Income Taxes	Cash Paid for Interest and Income Taxes (all amounts in thousands):

		Year Ended December 31,
		2014		2013
	Interest	$	592	$	1,693
	Income taxes		244		133

Non-Cash Investing and Financing Activities	Non-Cash Investing and Financing Activities (all amounts in thousands):

		Year Ended December 31,
		2014		2013
	Series A Convertible Preferred stock accrued dividend	$	509	$	55
	Series C Preferred stock accrued dividend		103		0
	Series A, Series B and Series C Preferred stock deemed dividends		4,921		4,000
	Adjustment to warrant liability upon warrant exercise		44		0
	Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP		241		0
	Issuance of 242,308 shares to related party		157		0
	Warrants liability recorded in connection with common and preferred warrants		0		5,607
	Litigation award payable accounted for as a receivable due from related party		0		134
	Amendment and adjustment to the fair value of warrants issued in conjunction with issuance of subordinated term loan recorded within warrant liability		0		241

Recovered_Sheet1

Background and Description of Business - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net Income (Loss) Attributable To Parent	($7,716)	($15,653)
Net Cash Provided By Used In Operating Activities	3,682	-2,607
Retained Earnings Accumulated Deficit	-103,590	-95,874
Cash	2,358	865	2,695
Stockholders Equity	$185	$6,504	$25,275

Significant_Accounting_Policie3

Significant Accounting Policies (Useful Lives Used For Amortization Of Intangible Assets) (Detail)	12 Months Ended
	Dec. 31, 2014
Intangible Assets Useful Life [Line Items]
Useful lives	20 years
Patented Technology [Member] \| Minimum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	0 years	[1]
Patented Technology [Member] \| Maximum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	20 years	[1]
Customer Relationships [Member] \| Minimum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	9 years
Customer Relationships [Member] \| Maximum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	13 years
Trademarks and Trade Names [Member] \| Minimum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	0 years	[2]
Trademarks and Trade Names [Member] \| Maximum [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	15 years	[2]
Noncompete Agreements [Member]
Intangible Assets Useful Life [Line Items]
Useful lives	5 years

[1]	Each patent has its own legal expiration date and, therefore, its own useful life. Generally, our patentsb legal lives begin when the related patent application is filed with the relevant government authority and ends 20 years thereafter. Amortization on patent costs begins when the relevant government authority approves the related patent. Patents that have been recorded as of December 31, 2014 are expected to expire by 2034. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on patents of approximately $5.3 million was recorded during 2014 (see Note 3).
[2]	Trademarks and trade names of CTI are deemed to have a useful life of 15 years. CTIbs trademarks and trade names are subject to annual impairment reviews as of August 31, and, if conditions warrant, interim reviews based upon their estimated fair value. Impairment charges, if any, are recorded in the period in which the impairment is determined. An intangible impairment loss on trade names of approximately $4.3 million was recorded during 2014 (see Note 3).

Significant_Accounting_Policie4

Significant Accounting Policies (Net Income (Loss) Per Common Share) (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Numerator (in thousands):
Net loss	($7,716)	($15,653)
Loss available to common stockholders - basic and diluted	-13,249	-21,261
Denominator:
Weighted average shares outstanding - basic and diluted	21,294,432	20,714,531
Loss per common share:
Basic and diluted loss per common share	($0.62)	($1.03)
Series A convertible preferred stock dividends [Member]
Numerator (in thousands):
Preferred stock dividends	-509	-55
Series C preferred stock dividends [Member]
Numerator (in thousands):
Preferred stock dividends	-103	0
Series A Deemed Dividend [Member]
Numerator (in thousands):
Deemed dividend	-2,422	-5,553
Series B Deemed Dividend [Member]
Numerator (in thousands):
Deemed dividend	-1,098	0
Series C Deemed Dividend [Member]
Numerator (in thousands):
Deemed dividend	($1,401)	$0

Significant_Accounting_Policie5

Significant Accounting Policies (Dilutive Common Share Equivalents Were Excluded From The Calculation Of Diluted Net Income Per Common Share) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,347,322	2,852,186
Series A convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	33,401,765	6,153,850
Series B convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	35,713,147	0
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	455,514	528,523
Warrant [Member] \| Series A convertible preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	174,404	174,404
Restricted stock awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	34,266
Convertible notes payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,666,667	2,666,667
Amended related party note [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,997,074	1,538,450

Significant_Accounting_Policie6

Significant Accounting Policies (Additional Information) (Detail) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 30, 2014	Nov. 19, 2013
Significant Accounting Policies [Line Items]
Shipping, Handling and Transportation Costs		$358,000	$423,000
Advertising Expense		151,000	215,000
Impairment Of Intangible Assets, Finite-Lived	875,000	9,580,000	875,000	281,000
Warrant Shares Increased					174,404
Common Stock [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		528,523
Preferred Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		6,153,850	6,153,850
Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		455,514	528,523
Series A Preferred Stock [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights					123,077
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		33,401,765	6,153,850
Series A Preferred Stock [Member] \| Preferred Warrant [Member]
Significant Accounting Policies [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights						123,077
Series A Preferred Stock [Member] \| Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		174,404	174,404
Patents [Member]
Significant Accounting Policies [Line Items]
Impairment Of Intangible Assets, Finite-Lived		5,300,000
Trade Names [Member]
Significant Accounting Policies [Line Items]
Impairment Of Intangible Assets, Finite-Lived		$4,300,000
Equipment [Member] \| Maximum [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		8 years
Equipment [Member] \| Minimum [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		4 years
Building Improvements [Member]
Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Useful Life		30 years

Impairment_Charges_Additional_

Impairment Charges (Additional Information) (Detail) (USD $)	3 Months Ended	12 Months Ended			3 Months Ended
	Jun. 30, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets	$875,000	$9,580,000	$875,000	$281,000
Goodwill, Impairment Loss		0	168,000	47,100,000
Property, Plant and Equipment [Member]
Asset Impairment Charges [Line Items]
Asset Impairment Charges				273,000
Customer Relationships [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets			650,000
Chemical Light [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets					9,600,000
Patents [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets			174,000		5,300,000
Trademarks and Trade Names [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets			17,000		4,300,000
Non Compete Agreement [Member]
Asset Impairment Charges [Line Items]
Impairment loss on intangible assets			$34,000

Inventories_Schedule_Of_Invent

Inventories (Schedule Of Inventories) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]
Raw materials	$4,777	$6,535
Work-in-process	1,546	2,185
Finished goods	1,503	2,062
Inventory, Net	$7,826	$10,782

Prepaid_Expenses_And_Other_Cur2

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Value added taxes receivable	$30	$17
Prepaid expenses	495	312
Debt issuance costs, current portion	21	53
Other	102	81
Prepaid expenses and other current assets total	$648	$463

Property_Plant_And_Equipment_S

Property, Plant And Equipment (Schedule Of Property Plant And Equipment) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Land	$1,267	$1,285
Building and improvements	3,564	3,332
Machinery and equipment	8,408	8,300
Leasehold improvements	275	266
Furniture and fixtures	131	122
Software	132	59
Property, Plant and Equipment, Gross	13,777	13,364
Less: accumulated depreciation and amortization	-6,657	-5,363
Property, Plant and Equipment, Net	$7,120	$8,001

Goodwill_Schedule_Of_Goodwill_

Goodwill (Schedule Of Goodwill, Impairment Loss) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Goodwill [Line Items]
Beginning balance	$7,992	[1]	$8,160
Impairment loss (see Notes 3 and 23)	0		-168		-47,100
Ending balance	7,992	[1]	7,992	[1]	8,160
CSP [Member]
Goodwill [Line Items]
Beginning balance	2,978	[1]	2,978
Impairment loss (see Notes 3 and 23)	0		0
Ending balance	2,978	[1]	2,978	[1]
Chemical Light [Member]
Goodwill [Line Items]
Beginning balance	5,014	[1]	5,182
Impairment loss (see Notes 3 and 23)	0		-168
Ending balance	$5,014	[1]	$5,014	[1]

[1]	Gross amount of goodwill was approximately $67.7 million as of December 31, 2014 and 2013. Accumulated impairment losses were approximately $59.7 million as of December 31, 2014 and 2013.

Goodwill_Additional_Informatio

Goodwill (Additional Information) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Goodwill, Gross	$67.70	$67.70
Goodwill, Impaired, Accumulated Impairment Loss	$59.70	$59.70

Other_Intangible_Assets_Schedu

Other Intangible Assets (Schedule Of Showing Of Components Of Other Intangible Assets) (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Cost	$18,542		$28,198
Accumulated Amortization	11,951		10,250
Net Book Value	6,591		17,948
Developed Technologies Including Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	8,736	[1]	13,853	[1]
Accumulated Amortization	6,582	[1]	5,720	[1]
Net Book Value	2,154	[1]	8,133	[1]
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,068	[2]	5,365	[2]
Accumulated Amortization	401	[2]	119	[2]
Net Book Value	667	[2]	5,246	[2]
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	8,562	[3]	8,812	[3]
Accumulated Amortization	4,858	[3]	4,336	[3]
Net Book Value	3,704	[3]	4,476	[3]
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	160	[4]	160	[4]
Accumulated Amortization	107	[4]	75	[4]
Net Book Value	53	[4]	85	[4]
Website Development Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	16		8
Accumulated Amortization	3		0
Net Book Value	$13		$8

[1]	Includes a patent obtained in the acquisition of CSP with a cost of $50,000 that is expected to be fully amortized in August 2026. Patents obtained in the acquisition of CTS with an initial cost of $410,000 and a December 31, 2012 gross value of approximately $238,000 were impaired by approximately $221,000 during 2013 (see Note 3 Impairment Charges) and the $17,000 of CTS patents remaining after the impairment was transferred to CTI in 2014. The CTI patents were impaired by approximately $5.3 million during 2014 (see Note 3 Impairment Charges).
[2]	Includes CTI trademarks and trade names which were impaired by approximately $4.3 million during 2014 (see Note 3 Impairment Charges).
[3]	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. Customer relationships obtained in the acquisition of CTS with a cost of $840,000 was impaired by approximately $780,000 during 2013 (see Note 3 Impairment Charges) and the $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.
[4]	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016. A non-compete agreement obtained in the acquisition of CTS with an initial cost of $140,000 was determined to be fully impaired in 2013 (see Note 3 Impairment Charges).

Other_Intangible_Assets_Future

Other Intangible Assets (Future Amortization Expense Related To Other Intangible Assets) (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
2015	$957
2016	947
2017	922
2018	910
2019	841
Thereafter	1,894
Total future amortization expense	$6,471

Other_Intangible_Assets_Additi

Other Intangible Assets (Additional Information) (Detail) (USD $)	3 Months Ended	12 Months Ended
	Jun. 30, 2013	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill)		$6,591,000		$17,948,000
Useful lives		20 years
Amortization Of Intangible Assets		1,812,000		1,796,000
Impairment Of Intangible Assets, Finite-Lived	875,000	9,580,000		875,000		281,000
Trademarks [Member]
Other Intangible Assets [Line Items]
Finite Lived Intangible Assets Cost Incurred To Create Or Defend		5,000		27,000
Patents [Member]
Other Intangible Assets [Line Items]
Finite Lived Intangible Assets Cost Incurred To Create Or Defend		160,000		342,000
Impairment Of Intangible Assets, Finite-Lived		5,300,000
Noncompete Agreements [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill)		53,000	[1]	85,000	[1]
Useful lives		5 years
Trade Names [Member]
Other Intangible Assets [Line Items]
Impairment Of Intangible Assets, Finite-Lived		4,300,000
Customer Relationships [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill)		3,704,000	[2]	4,476,000	[2]
Impairment Of Intangible Assets, Finite-Lived				650,000
Developed Technologies Including Patents [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill)		2,154,000	[3]	8,133,000	[3]
Cyalume Specialty Products Inc [Member] \| Patents [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		50,000
Cyalume Specialty Products Inc [Member] \| Noncompete Agreements [Member]
Other Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				34,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		160,000
Cyalume Specialty Products Inc [Member] \| Customer Relationships [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		920,000
Combat Training Solutions Inc [Member]
Other Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				650,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		840,000
Combat Training Solutions Inc [Member] \| Patents [Member]
Other Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				174,000
Intangible Assets, Gross (Excluding Goodwill), Total				238,000
Intangible Assets, Net (Excluding Goodwill)		17,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		410,000
Combat Training Solutions Inc [Member] \| Noncompete Agreements [Member]
Other Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		140,000
Combat Training Solutions Inc [Member] \| Trade Names [Member]
Other Intangible Assets [Line Items]
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)				17,000
Combat Training Solutions Inc [Member] \| Customer Relationships [Member]
Other Intangible Assets [Line Items]
Intangible Assets, Net (Excluding Goodwill)		$60,000

[1]	Includes a non-compete agreement obtained in the acquisition of CSP with a cost of $160,000 that is expected to be fully amortized in August 2016. A non-compete agreement obtained in the acquisition of CTS with an initial cost of $140,000 was determined to be fully impaired in 2013 (see Note 3 Impairment Charges).
[2]	Includes customer relationships obtained in the acquisition of CSP with a cost of $920,000 that is expected to be fully amortized in December 2019. Customer relationships obtained in the acquisition of CTS with a cost of $840,000 was impaired by approximately $780,000 during 2013 (see Note 3 Impairment Charges) and the $60,000 of CTS customer relationships remaining after the impairment was transferred to CTI in 2014.
[3]	Includes a patent obtained in the acquisition of CSP with a cost of $50,000 that is expected to be fully amortized in August 2026. Patents obtained in the acquisition of CTS with an initial cost of $410,000 and a December 31, 2012 gross value of approximately $238,000 were impaired by approximately $221,000 during 2013 (see Note 3 Impairment Charges) and the $17,000 of CTS patents remaining after the impairment was transferred to CTI in 2014. The CTI patents were impaired by approximately $5.3 million during 2014 (see Note 3 Impairment Charges).

Debt_Issuance_Costs_Additional

Debt Issuance Costs (Additional Information) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Amortization of Financing Costs	$42,000	$113,000
Unamortized Debt Issuance Expense	337,000	542,000
Interest Expense [Member]
Unamortized Debt Issuance Expense	$27,000

Accrued_Expenses_Schedule_Of_A

Accrued Expenses (Schedule Of Accrued Expenses) (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Accrued Expenses [Line Items]
Payroll-related	$834	[1]	$1,145	[1]
Interest payable	550		301
Subordinated term loan exit fee	285		30
Professional fees	87		26
Franchise and sales tax payable	50		51
Other	884		348
Accounts Payable and Accrued Liabilities	2,690		2,059
Selway Capital [Member]
Accrued Expenses [Line Items]
Related party payable	$0	[2]	$158	[2]

[1]	Accrued payroll-related costs as of December 31, 2014 include approximately $141,000 of accrued severance costs. Accrued payroll-related costs as of December 31, 2013 include approximately $534,000 of accrued severance costs.
[2]	See Note 13 for a description of the agreement with Selway Capital, LLC.

Accrued_Expenses_Additional_In

Accrued Expenses (Additional Information) (Detail) (Employee Severance [Member], USD $)	Dec. 31, 2014	Dec. 31, 2013
Employee Severance [Member]
Accrued Expenses [Line Items]
Payroll-related	$141,000	$534,000

Lines_Of_Credit_Additional_Inf

Lines Of Credit (Additional Information) (Detail)	Dec. 31, 2014	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	EUR (€)	Td Bank N. [Member]
			USD ($)
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$900,000	€ 750,000	$5,000,000
Line of Credit Facility, Interest Rate Description			Interest is payable monthly and is determined based on the Prime Rate, plus 3%
Line of Credit Facility, Interest Rate During Period			6.25%
Line of Credit Facility, Amount Outstanding			2,100,000
Line of Credit Facility, Remaining Borrowing Capacity	$594,000
Line of Credit Facility, Expiration Date			19-Dec-15

Notes_Payable_Outstanding_Note

Notes Payable (Outstanding Notes Payable) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Senior Debt - Term Loan	$4,239	$6,023
Senior Debt - Real Estate Loan	1,551	1,679
Subordinated Term Loan	9,676	8,659
Promissory Note Payable	860	1,075
Total	16,326	17,436
Less: Unamortized debt discount	-337	-542
Less: Current portion of notes payable, including current portion of unamortized debt discount	-5,775	-1,925
Notes payable, net of current portion	$10,214	$14,969

Notes_Payable_Carrying_Value_o

Notes Payable (Carrying Value of The Subordinated Term Loan) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Principal amount of loan	$9,676	$8,659
Less: unamortized debt discount	-285	-424
Notes and Loans Payable	$9,391	$8,235

Notes_Payable_Interest_Costs_F

Notes Payable (Interest Costs For The Subordinated Term Loan) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Subordinated Term Loan [Line Items]
Contractual interest coupon rate	$1,153	$949
Amortization of related debt discount and debt issuance costs	221	486
Total interest expense recognized	$1,374	$1,435

Notes_Payable_Future_Minimum_P

Notes Payable (Future Minimum Payments Due For Notes Payable) (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
2015	$6,005
2016	9,891
2017	215
2018	215
2019	0
Thereafter	0
Long-term Debt	$16,326

Notes_Payable_Additional_Infor

Notes Payable (Additional Information) (Detail) (USD $)	12 Months Ended			1 Months Ended
Notes Payable (Additional Information) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 19, 2013	Jul. 29, 2010	Dec. 31, 2010	Dec. 19, 2013
Notes Payable [Line Items]
Long term debt maturities, 2015	$6,005,000
Description of Interest Rate Cash Flow Hedge Activities	The total interest rate on the swapped portion of the Term Loan was changed from 6.53% to 6.25% on December 19, 2013 and was 6.25% at December 31, 2014. Interest on the remaining 40% of the Term Loan that was not subject to an interest rate hedging relationship was at 6.25% at December 31, 2014 and at December 31, 2013. The Term Loan is collateralized by all of the assets of CTI (except CTI’s equity interests in CTSAS, of which only 65% is collateral of the Term Loan) and is guaranteed by Cyalume.
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.01
Amendment and adjustment to the fair value of warrants issued in conjunction with issuance of subordinated term loan recorded within warrant liability	0	-241,000	94,000
Amortization of Debt Discount (Premium)	205,000	520,000
Common Stock To Purchase Of Warrants	25,000	455,514
Debt Instrument, Face Amount	9,676,000	8,659,000
Promissory Notes Payable [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				2.00%
Debt Instrument, Periodic Payment				215,000
Debt Instrument, Face Amount				1,075,000
Subordinated Term Loan [Member]
Notes Payable [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						160,000
Class of Warrant or Right, Exercise Price of Warrants or Rights						$1.50
Amendment and adjustment to the fair value of warrants issued in conjunction with issuance of subordinated term loan recorded within warrant liability	-207,000
Debt Instrument, Interest Rate, Effective Percentage	13.00%
Subordinated Term Loan [Member] \| Before Amendment [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Effective Percentage	17.00%
Term Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Periodic Payment, Principal	148,000
Long term debt maturities, 2015	2,500,000
Debt Instrument, Interest Rate, Stated Percentage	6.25%
Term Loan [Member] \| Maximum [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							6.53%
Term Loan [Member] \| Minimum [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							6.25%
Swapped Portion Of Term Loan [Member]
Notes Payable [Line Items]
Percentage of Debt Hedged by Interest Rate Derivatives	60.00%
Real Estate Loan [Member]
Notes Payable [Line Items]
Debt Instrument, Periodic Payment, Principal	10,000
Long term debt maturities, 2015	1,400,000
Debt Instrument, Interest Rate, Stated Percentage	6.25%
Real Estate Loan [Member] \| Maximum [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							6.42%
Real Estate Loan [Member] \| Minimum [Member]
Notes Payable [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							6.25%
Granite Creek Partners Agent Llc [Member]
Notes Payable [Line Items]
Subordinated Borrowing, Interest Rate					11.00%
Debt Instrument Convertible Number Of Equity Instrument					2,666,667
Share Price	$0.05
Debt Instrument, Convertible, Conversion Price					$3.19
Debt Instrument Convertible If Converted Value Less Than Principal	100,000
Impaired Financing Receivable, Unpaid Principal Balance, Total	9,500,000
Issuance Of Loan					8,500,000
Debt Instrument, Face Amount			$8,500,000

Related_Party_Transactions_Add

Related Party Transactions (Additional Information) (Detail) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 30, 2014	Jan. 31, 2014	Nov. 19, 2013
Related Party Transaction [Line Items]
Gains (Losses) on Extinguishment of Debt, Total	($527,000)	($2,142,000)
Class of Warrant or Right, Exercise Price of Warrants or Rights		$0.01
Sale of Stock, Price Per Share		$0.69
Other Liabilities, Current	0	242,000
Common Stock Closing Price		1.75
Conversion of Stock, Amount Converted	401,000
Convertible Preferred Stock, Shares Issued upon Conversion	50		7,318,187
Convertible Preferred Stock Conversion Price	$0.65		0.13664587
Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of Stock, Shares Converted			30,769
Conversion of Stock, Amount Converted	0
Jfc [Member]
Related Party Transaction [Line Items]
Long-term Line of Credit			5,000,000
Gains (Losses) on Extinguishment of Debt, Total		2,100,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						73,009
Class of Warrant or Right, Exercise Price of Warrants or Rights						$0.01
Stock Issued During Period, Shares, New Issues			350,000
Class Of Warrant Or Right, Outstanding					350,000
Unsecured Debt			2,100,000
Seller Of Csp [Member]
Related Party Transaction [Line Items]
Monthly Lease Payments Due To Related Parties	30,000
Amended JFC Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Gains (Losses) on Extinguishment of Debt, Total	500,000
Debt Instrument, Convertible, Conversion Price			32.5
Convertible Debt			1,000,000
Amended JFC Note [Member] \| Series A Preferred Stock [Member]
Related Party Transaction [Line Items]
Conversion of Stock, Amount Converted			1,000,000
Selway [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues				242,308
Due To Related Party For Services	$11,000			$157,000

Income_Taxes_The_Components_of

Income Taxes (The Components of Income (Loss) Before Income Taxes) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Domestic	($7,569)	($18,866)
Foreign	1,091	175
Loss before income taxes	($6,478)	($18,691)

Income_Taxes_Benefit_From_Inco

Income Taxes (Benefit From Income Taxes Consisted) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$223	$0
State	156	160
Foreign	443	130
Deferred:
Federal	2,008	-2,678
State	-1,513	-595
Foreign	-79	-55
Provision for (benefit from) income taxes	$1,238	($3,038)

Income_Taxes_The_Consist_of_De

Income Taxes (The Consist of Deferred Income Tax Assets And Liabilities) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current	$735	$4,502
Deferred tax assets, Non-current	2,930	4,943
Valuation allowance, Current	-2,741	-2,747
Valuation allowance, Non-current	-10,353	-3,175
Deferred tax liabilities, Current	-1,040	-655
Deferred tax liabilities, Non-current	-3,055	-8,790
Deferred tax assets (liabilities), Current	-305	3,847
Deferred tax assets (liabilities), Noncurrent	-430	-3,847
Federal [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current	2,699	6,329
Deferred tax assets, Non-current	11,857	7,230
Deferred tax liabilities, Current	-805	-477
Deferred tax liabilities, Non-current	-2,103	-6,615
State [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current	777	886
Deferred tax assets, Non-current	1,426	868
Deferred tax liabilities, Current	-219	-124
Deferred tax liabilities, Non-current	-538	-1,697
Foreign [Member]
Schedule Of Deferred Income Tax Assets And Liabilities [Line Items]
Deferred tax assets, Current	0	34
Deferred tax assets, Non-current	0	20
Deferred tax liabilities, Current	-16	-54
Deferred tax liabilities, Non-current	($414)	($478)

Income_Taxes_Principal_Compone

Income Taxes (Principal Components Of Our Net Liability Representing Deferred Income Tax Balances) (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Intangible assets	$178		($3,778)
Property, plant and equipment	-661		-740
U.S. loss carryforwards and tax credits, net	10,151	[1]	8,974	[1]
Subsidiary income	-764	[2]	-1,671	[2]
Stock-based compensation expense	1,142		968
Reserves, accruals and other	1,664		1,292
State deferred tax asset	954		0
Change in warrants fair value	0		877
Valuation allowance	-13,094		-5,922
Deferred Tax Assets, Net, Total	($430)		$0

[1]	The Company had federal net operating loss carryforwards amounting to approximately $7.9 million and $13.3 million at December 31, 2014 and 2013, respectively. The net operating loss carryforward at December 31, 2014 expires in fiscal years 2026 through 2034. Internal Revenue Code Section 382 limits utilization of these losses to approximately $0.8 million per year. It is possible that future changes in ownership could result in changes to the amounts allowed by IRC Section 382. State net operating loss carryforwards amounted to approximately $10.3 million and $2.0 million as of December 31, 2014 and 2013, respectively.
[2]	A deferred tax liability has been recorded for income taxes which may become payable upon distribution of earnings of CTSAS, our French subsidiary. The estimated amount of tax that might be payable with regard to any distribution for foreign subsidiary earnings is reported net of foreign taxes paid, which are creditable against our domestic tax liability. The Company does not permanently reinvest foreign subsidiary earnings. The Company continually evaluates this assertion; if the Companybs foreign business needs change, so may this assertion.

Income_Taxes_Principal_Compone1

Income Taxes (Principal Components Of Our Net Liability Representing Deferred Income Tax Balances) (Parenthetical) (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	7.9	$13.30
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	10.3	9.9
Limitations On Use Operating Loss Carryforwards	0.8
Maximum [Member]
Operating Loss Carryforwards Expiration Year	2034
Minimum [Member]
Operating Loss Carryforwards Expiration Year	2026

Income_Taxes_The_Federal_Statu

Income Taxes (The Federal Statutory Income Tax Rate Differs From Our Effective Tax Rate) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Provision for federal income taxes expected at 34% statutory rate	($2,201)	($6,355)
Increase (reduction) resulting from:
Tax on global activities, net of foreign tax credits	-2,842	2
State income taxes, less federal income tax benefit	-895	-287
Loss on debt extinguishment	179	728
Change in valuation allowance	7,172	3,507
Change in fair value of warrants	-1,518	0
Goodwill impairment loss	0	57
Prior year true up	1,008	-715
Other	335	25
Benefit from income taxes	$1,238	($3,038)

Income_Taxes_The_Federal_Statu1

Income Taxes (The Federal Statutory Income Tax Rate Differs From Our Effective Tax Rate) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%

Capital_Lease_Obligations_Addi

Capital Lease Obligations (Additional Information) (Detail) (USD $)	Dec. 31, 2014
Capital Leases, Future Minimum Payments Due	$7,000

Recovered_Sheet2

Derivative Instruments and Hedging Activities (Additional Information) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2008
Derivative [Line Items]
Interest rate swap assumed hedge effectiveness		100.00%
Maximum [Member]
Derivative [Line Items]
Currency forward contract, duration	6 months

Asset_Retirement_Obligation_Th

Asset Retirement Obligation (The Significant Assumptions Used To Estimate The Obligation) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Asset Retirement Obligation Disclosure [Line Items]
Annual inflation rate	5.54%
Credit-adjusted risk-free rate	5.37%
Initial estimated remediation costs (undiscounted and not adjusted for inflation)	$200,000
Estimated remediation completion date	19-Dec-38
Estimated remediation cost on December 19, 2038	$720,000

Asset_Retirement_Obligation_Re

Asset Retirement Obligation (Reconciliation of The Beginning And Ending Aggregate Carrying Amounts Of The Asset Retirement Obligation) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Asset Retirement Obligation Disclosure [Line Items]
Balance, beginning	$194		$184
Accretion expense	10		10
Balance, ending	$204	[1]	$194

[1]	The difference between the $204,000 liability as of December 31, 2014 and the estimated undiscounted future payments of $720,000 is estimated inflation between December 31, 2014 and December 19, 2038.

Asset_Retirement_Obligation_Re1

Asset Retirement Obligation (Reconciliation of The Beginning And Ending Aggregate Carrying Amounts Of The Asset Retirement Obligation) (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2007
Asset Retirement Obligation Disclosure [Line Items]
Undiscounted and not adjusted for inflation	$41,000

Commitments_And_Contingencies_1

Commitments And Contingencies (Future Minimum Lease Payments) (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified	Dec. 31, 2014
Commitments and Contingencies Disclosure [Line Items]
2015	$595
2016	480
2017	242
2018	59
2019	0
Thereafter	0
Operating Leases, Future Minimum Payments Due	$1,376

Commitments_And_Contingencies_2

Commitments And Contingencies (Additional Information) (Detail) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Nov. 20, 2013	Nov. 19, 2013	Jul. 18, 2011	Aug. 31, 2013
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Settlement Agreement, Terms	Pursuant to the Omniglow Settlement Agreement, CTI agreed to either pay the full settlement amount of approximately $4.5 million or satisfy the settlement amount as follows: (i) an initial payment of $250,000, (ii) transfer the 625,139 Escrowed Shares, (iii) payment of $1.0 million in cash within 21 days from the execution of the Omniglow Settlement Agreement and (iv) additional payments in cash and/or through cooperative marketing credits of $1.9 million if paid within 18 months from the date of the Omniglow Settlement Agreement, or of approximately $2.4 million if paid within 27 months from the date of the Omniglow Settlement Agreement.
Future Minimum Lease Payments, Required Per Month						$24,000
Payments for Legal Settlements	1,465,000	275,000
Escrow Shares Fair Value		625,139
Loss Contingency Accrual, Beginning Balance	2,700,000
Promissory Note [Member]
Commitments and Contingencies Disclosure [Line Items]
Repayments of Debt	215,000
Mr.Colon [Member]
Commitments and Contingencies Disclosure [Line Items]
Payments for Legal Settlements			275,000
Mr.Colon [Member] \| Promissory Note [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Amount				1,075,000
Mr.Colon [Member] \| Five Year Annal Installments [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Amount				215,000
Omniglow [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Awarded, Value					2,600,000
Prejudgment Interest Rate					12.00%
Loss contingency damages awarded accrued interest					1,300,000
Omniglow [Member] \| Attorney Fees and Costs [Member]
Commitments and Contingencies Disclosure [Line Items]
Loss Contingency, Damages Awarded, Value					235,000
Prejudgment Interest Rate					12.00%
Newmark Knight and Frank [Member]
Commitments and Contingencies Disclosure [Line Items]
Future Minimum Lease Payments, Required Per Month	30,000
Operating Leases [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense	$756,000	$638,000

Preferred_Stock_Schedule_Of_Ch

Preferred Stock (Schedule Of Change In The Fair Value Of The Warrants Liability) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2013	$6,373
Warrants amended in connection with refinancing	72
Warrant exercise	-44
Change in fair value of warrants	4,852	-525
Termination of Common and Preferred Warrants	1,525
Warrant liability at December 31, 2014	25	6,373
Common Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2013	4,081
Warrants amended in connection with refinancing	0
Warrant exercise	0
Change in fair value of warrants	-3,331
Termination of Common and Preferred Warrants	-750
Warrant liability at December 31, 2014	0
Preferred Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2013	1,997
Warrants amended in connection with refinancing	0
Warrant exercise	0
Change in fair value of warrants	-1,223
Termination of Common and Preferred Warrants	-774
Warrant liability at December 31, 2014	0
JFC Warrant [Member]
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2013	54
Warrants amended in connection with refinancing	0
Warrant exercise	-44
Change in fair value of warrants	-10
Termination of Common and Preferred Warrants	0
Warrant liability at December 31, 2014	0
Subordinated Term Loan Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant liability at December 31, 2013	241
Warrants amended in connection with refinancing	72
Warrant exercise	0
Change in fair value of warrants	-288
Termination of Common and Preferred Warrants	0
Warrant liability at December 31, 2014	$25

Preferred_Stock_Additional_Inf

Preferred Stock (Additional Information) (Detail) (USD $)	1 Months Ended	12 Months Ended			1 Months Ended
Preferred Stock (Additional Information) (Detail) (USD $)	Jul. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 19, 2013
Preferred Stock Disclosure [Line Items]
Sale of Stock, Price Per Share			$0.69
Preferred Stock, Liquidation Preference Per Share		$32.50
Convertible Preferred Stock, Shares Issued upon Conversion		50		7,318,187
Convertible Preferred Stock Conversion Price		$0.65		0.13664587
Conversion Price		$0.14
Fair Value Adjustment of Warrants		($4,852,000)	$525,000
Preferred Stock Fair Value Estimated	1,600,000
Proceeds from Issuance of Preferred Stock and Preference Stock		2,000,000	4,000,000
Percentage Of Common Stock Outstanding	40.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights			$0.01
Series A Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock Par Or Stated Value Per Share	$0.00
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights	123,077
Preferred Stock Dividends, Income Statement Impact	2,400,000	-509,000	-55,000
Conversion of Stock, Shares Converted				30,769
Series A Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized		1,000,000	1,000,000
Preferred Stock Par Or Stated Value Per Share		$0.00	$0.00
Preferred Stock, Dividend Rate, Percentage		12.00%
Preferred Stock Dividends, Income Statement Impact		509,000	55,000
Series C Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized		1,000,000
Preferred Stock Par Or Stated Value Per Share	$0.00	$0.00
Preferred Stock Dividends, Income Statement Impact		103,000	0
Proceeds from Issuance of Preferred Stock and Preference Stock	600,000
Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Shares Authorized		1,000,000
Preferred Stock Par Or Stated Value Per Share		$0.00
Proceeds from Issuance of Preferred Stock and Preference Stock	1,300,000
Conversion of Stock, Shares Converted	35,713.15
Preferred Stock Liquidation Preference Description		Liquidation Value is the greater of (1) 150% of the Purchase Price ($3,000 per share) or (2) the Base Value ($2,000 per share plus accrued and unpaid dividends).
Series B Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	1,400,000
Convertible To Common Stock Fair Value	2,500,000
Preferred Stock Beneficial Conversion Feature	1,100,000
Series B And C Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Proceeds from Issuance of Preferred Stock and Preference Stock	2,000,000
Series C Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Dividend Rate, Percentage		12.00%
Dividends, Preferred Stock, Paid-in-kind		2,000
Preferred Stock Dividend Payable Percentage Of Shares		75.00%
Series C Convertible Preferred Stock [Member] \| Minimum [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Liquidation Preference Per Share		$3,000
Series C Convertible Preferred Stock [Member] \| Maximum [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Liquidation Preference Per Share		$2,000
Common Warrant [Member]
Preferred Stock Disclosure [Line Items]
Fair Value Adjustment of Warrants		3,331,000
Common Warrant [Member] \| Series A Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights					6,153,830
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.65
Preferred Warrant [Member]
Preferred Stock Disclosure [Line Items]
Fair Value Adjustment of Warrants		1,223,000
Preferred Warrant [Member] \| Series A Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights					123,077
Class of Warrant or Right, Exercise Price of Warrants or Rights					$0.05
Preferred Warrant [Member] \| Series C Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Fair Value Adjustment of Warrants	1,500,000
Preferred Warrant [Member] \| Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Fair Value Adjustment of Warrants	1,500,000
Purchase Agreement [Member]
Preferred Stock Disclosure [Line Items]
Stock Issued During Period, Shares, Other	1,000
Stock Issued During Period, Value, Other	$2,000,000				$4,000,000
Sale of Stock, Price Per Share	$2,000				$32.50
Purchase Agreement [Member] \| Series A Convertible Preferred Stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock Par Or Stated Value Per Share					$0.00
Purchase Agreement [Member] \| Series B convertible preferred stock [Member]
Preferred Stock Disclosure [Line Items]
Preferred Stock, Conversion Basis	if the Company issues or sells shares of Common Stock or other equity securities for no consideration or for consideration that is based on an equity valuation of the Company of less than $2 million in the aggregate (a “Trigger Issuance”). In the event of a Trigger Issuance, the Conversion Number shall be increased as of the close of business on the effective date of the Trigger Issuance to a number calculated as follows: (i) two-thirds of the Common Stock deemed Outstanding (as defined in the Series A Certificate of Designation) immediately following such Trigger Issuance (excluding any Common Stock Deemed Outstanding as a result of the conversion of the Series B Preferred Stock) (ii) divided by 1,000. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on the tenth anniversary of its original issuance date, at the then-current Conversion Number.
Conversion of Stock, Shares Converted	1,000

Stockholders_Equity_Warrants_T

Stockholders' Equity (Warrants To Purchase Common Stock Outstanding) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Granite Creek FlexCap I, L.P [Member]
Class of Warrant or Right [Line Items]
Number of Shares Exercisable Under Warrant	267,950
Exercise Price	$0.01
Expiration Date	19-Nov-23
Patriot Capital II, L.P [Member]
Class of Warrant or Right [Line Items]
Number of Shares Exercisable Under Warrant	187,564
Exercise Price	$0.01
Expiration Date	19-Nov-23

Stockholders_Equity_ShareBased

Stockholders' Equity (Share-Based Expenses Are Included In Our Consolidated Statements Of Comprehensive Income (Loss) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$394	$773
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	9	9
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	38	44
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	331	621
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$16	$99

Stockholders_Equity_The_BlackS

Stockholders' Equity (The Black-Scholes Pricing Model With The Following Assumptions For Awards To Employees And Non-Employees) (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (Minimum)	1.83%	1.10%
Risk-free interest rate (Maximum)	2.31%	1.70%
Estimated dividend yield	0.00%	0.00%
Volatility (Minimum)	143.89%	126.71%
Volatility (Maximum)	144.45%	130.08%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	10 years	6 years 6 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 3 months 18 days	5 years

Stockholders_Equity_Stock_Opti

Stockholders' Equity (Stock Option And Warrant Activity Related To Share-Based Compensation) (Detail) (USD $)	1 Months Ended	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Nov. 21, 2014	Dec. 31, 2014		Dec. 31, 2013
Outstanding Shares, Beginning		2,852		2,842
Shares Granted		9,197	[1]	708	[2]
Shares Exercised		0		0
Shares Forfeited		-1,520		-415
Shares Expired		-182		-283
Outstanding Shares, Ending		10,347	[3]	2,852
Shares Exercisable		803	[4]
Outstanding Weighted Average Exercise Price, Beginning		$2.10		$2.33
Weighted Average Exercise Price Granted	$0.09	$0.09	[1]	$1.79	[2]
Weighted Average Exercise Price Exercised		$0		$0
Weighted Average Exercise Price Forfeited		$1.52		$2.02
Weighted Average Exercise Price Expired		$3.04		$3.78
Outstanding Weighted Average Exercise Price, Ending		$0.38		$2.10
Weighted Average Exercise Price Exercisable		$3.21

[1]	The weighted-average grant-date fair value of awards granted was $0.09.
[2]	The weighted-average grant-date fair value of awards granted was $1.61.
[3]	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014.
[4]	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014. The weighted-average remaining contractual term for these options is 5.74 years as of December 31, 2014.

Stockholders_Equity_Stock_Opti1

Stockholders' Equity (Stock Option And Warrant Activity Related To Share-Based Compensation) (Parenthetical) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Weighted-average grant-date fair value	$1.61
Intrinsic value of awards exercised	$0.09

Stockholders_Equity_Stock_Opti2

Stockholders' Equity (Stock Options And Warrants Related To Stock-Based Compensation) (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding (in thousands)	10,347	[1]	2,852	2,842
Options Outstanding Weighted Average Remaining Contractual Term (Years)	9 years 6 months 4 days
Options Outstanding Weighted Average Exercise Price	$0.38		$2.10	$2.33
Options Exercisable Number Exercisable (in thousands)	803	[2]
Options Exercisable Weighted Average Exercise Price	$3.21
Range Of Exercise Prices 0.00 - 2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding (in thousands)	9,698
Options Outstanding Weighted Average Remaining Contractual Term (Years)	9 years 9 months 22 days
Options Outstanding Weighted Average Exercise Price	$0.17
Options Exercisable Number Exercisable (in thousands)	156
Options Exercisable Weighted Average Exercise Price	$1.68
Range Of Exercise Prices 2.01 - 4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding (in thousands)	524
Options Outstanding Weighted Average Remaining Contractual Term (Years)	4 years 11 months 16 days
Options Outstanding Weighted Average Exercise Price	$3.33
Options Exercisable Number Exercisable (in thousands)	522
Options Exercisable Weighted Average Exercise Price	$3.33
Range Of Exercise Prices 4.01 - 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number Outstanding (in thousands)	125
Options Outstanding Weighted Average Remaining Contractual Term (Years)	5 years 11 months 8 days
Options Outstanding Weighted Average Exercise Price	$4.61
Options Exercisable Number Exercisable (in thousands)	125
Options Exercisable Weighted Average Exercise Price	$4.61

[1]	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014.
[2]	The aggregate intrinsic value of these stock options and warrants is $0 as of December 31, 2014. The weighted-average remaining contractual term for these options is 5.74 years as of December 31, 2014.

Stockholders_Equity_Stock_Opti3

Stockholders' Equity (Stock Options And Warrants Related To Stock-Based Compensation) (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Options Outstanding, Intrinsic Value	$0
Options Exercisable, Intrinsic Value	$0
Options Exercisable, Weighted-average remaining contractual term	5 years 8 months 26 days

Stockholders_Equity_Accumulate

Stockholders' Equity (Accumulated other comprehensive loss) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Foreign currency translation loss	($661)	($218)	($418)
Unrealized gain on cash flow hedges, net of taxes	0	0	-97
Accumulated other comprehensive loss	($661)	($218)

Stockholders_Equity_Changes_In

Stockholders' Equity (Changes In Accumulated Other Comprehensive Loss Due To Derivative Instruments And Hedging Activities) (Detail) (USD $)	12 Months Ended		24 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014
Beginning balance	$0	($97)	($97)
Unrealized gain on cash flow hedges, net of taxes of $(59) during 2013	0	97	97
Ending balance	$0	$0	$0

Stockholders_Equity_Changes_In1

Stockholders' Equity (Changes In Accumulated Other Comprehensive Loss Due To Derivative Instruments And Hedging Activities) (Parenthetical) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Unrealized gain on cash flow hedges, net of taxes	($59)

Stockholders_Equity_Changes_In2

Stockholders' Equity (Changes In Accumulated Other Comprehensive Loss Due To Currency Translation Adjustments) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Beginning balance	($218)	($418)
Adjustments due to translation of CTSAS financial statements from Euros into U.S. Dollars	-443	200
Ending balance	($661)	($218)

Stockholders_Equity_Additional

Stockholders' Equity (Additional Information) (Detail) (USD $)	1 Months Ended	12 Months Ended
	Nov. 21, 2014	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Stockholders Equity Additional Information [Line Items]
Common stock, shares authorized		100,000,000		100,000,000
Stock-based compensation expense		$394,000		$773,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$400,000	$977,000
Stock Options Awarded Vest Period		5 years
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period		1,520,000		415,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross		9,197,000	[1]	708,000	[2]
Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price	$0.09	$0.09	[1]	$1.79	[2]
Chief Operating Officer [Member]
Stockholders Equity Additional Information [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	350,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	1,504,767
Chief Executive Officer [Member]
Stockholders Equity Additional Information [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period	1,036,104
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross	5,015,891
Senior Amendment [Member]
Stockholders Equity Additional Information [Line Items]
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights		455,514
Unrestricted Stock Awards [Member] \| 2009 Equity Incentive Plan
Stockholders Equity Additional Information [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		2,650,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,150,082
Unrestricted Stock Awards [Member] \| 2014 Equity Incentive Plan
Stockholders Equity Additional Information [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		2,676,582
Stock Option And Warrant Awards [Member]
Stockholders Equity Additional Information [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition		7 years 8 months 19 days
Subordinated Debt [Member]
Stockholders Equity Additional Information [Line Items]
Class of Warrant or Right, Outstanding						160,000

[1]	The weighted-average grant-date fair value of awards granted was $0.09.
[2]	The weighted-average grant-date fair value of awards granted was $1.61.

Employee_Benefit_Plans_Additio

Employee Benefit Plans (Additional Information) (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	The CTI Employee Savings and Retirement Plan (the “ESRP”), is intended to be qualified under Section 401(k) of the Internal Revenue Code. Employees of CTI, CTS and CSP who have reached the age of 18 are eligible for participation on the first entry date after three months of service. Entry dates are the first day of January, April, July and October. Employees may defer receiving compensation up to the maximum amount permitted under the Internal Revenue Code. Matching contributions to the ESRP equal (i) 3% of employee compensation plus (ii) 50% of the next 2% of employee compensation. For the years ended December 31, 2014 and 2013, employer matching contributions were approximately $58,000 and $263,000, respectively.
Defined Contribution Plan Employer Matching Contribution Annual Amount	$58,000	$263,000
Defined Benefit Plan, Benefit Obligation	$78,000	$79,000

Concentrations_Additional_Info

Concentrations (Additional Information) (Detail) (USD $)	12 Months Ended
Concentrations (Additional Information) (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Concentration Risk [Line Items]
Insurance Coverage		250,000
Cash, Uninsured Amount	790,000
Insurance Coverage Exceed Limits		1,500,000
Outside United States Customer [Member] \| Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	52.00%	32.00%
CTSAS [Member]
Concentration Risk [Line Items]
Assets, Net	3,362,000	5,245,000
United Kingdom [Member] \| Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	12.00%	5.00%
One Customers [Member] \| Sales [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	41.00%	23.00%
Three Customers [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	49.00%	47.00%
Other Customer [Member] \| Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%	10.00%

Recovered_Sheet3

Fair Values Of Assets And Liabilities (Assets And Liabilities Measured At Fair Value On Recurring Basis) (Detail) (USD $)	Dec. 31, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	($25)	[1]	($6,373)	[1]
Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	-25	[1]	-6,373	[1]
Level 1 Quoted Prices in Active Markets for Identical Assets [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]	0	[1]
Level 1 Quoted Prices in Active Markets for Identical Assets [Member] \| Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]	0	[1]
Level 2 Significant Other Observable Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]	0	[1]
Level 2 Significant Other Observable Inputs [Member] \| Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	0	[1]	0	[1]
Level 3 Significant Unobservable Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	-25	[1]	-6,373	[1]
Level 3 Significant Unobservable Inputs [Member] \| Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring Basis	($25)	[1]	($6,373)	[1]

[1]	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.

Recovered_Sheet4

Fair Values Of Assets And Liabilities (Consideration Liability Measured at Fair Value on Recurring Basis) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period	$6,373	[1]
Warrants amended in connection with refinancing	72
Warrant exercise	-44
Termination of common and preferred warrants	1,525
Balance at the end of period	25	[1]
Contingent Consideration [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at the end of period	25	[1]	6,373	[1]
Warrants Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance at the beginning of period	6,373		0
Warrants amended in connection with refinancing	72		0
Warrant exercise	-44		0
Termination of common and preferred warrants	-1,524		0
Change in fair value of warrants	-4,852		525
Fair value recorded on the November 19, 2013 transaction date	0		5,848
Balance at the end of period	$25		$6,373

[1]	The Company has classified its warrants liability which could be potentially settled in cash within Level 3 because the fair values are determined using significant unobservable inputs into the Black-Scholes pricing model or the Monte Carlo simulation method.

Fair_Values_Of_Assets_And_Liab2

Fair Values Of Assets And Liabilities (Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Goodwill [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit			CTS Training	[1],[2]
Loss Recognized			$168	[2]
Fair Value			0	[2]
Patents [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit	Chemical Light	[1],[3]	CTS Training	[1],[3]
Loss Recognized	5,277	[3]	174	[3]
Fair Value	2,154	[3]	17	[3]
Trade Name [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit	Chemical Light	[1],[4]	CTS Training	[1],[4]
Loss Recognized	4,303	[4]	17	[4]
Fair Value	667	[4]	0	[4]
Non Compete Agreement [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit			CTS Training	[1],[5]
Loss Recognized			34	[5]
Fair Value			0	[5]
Customer Relationships [Member]
Fair Value, Assets Measured on Non-Recurring Basis, Unobservable Input Reconciliation
Cyalume Reporting Unit			CTS Training	[1]
Loss Recognized			650
Fair Value			$60

[1]	The Company is managed as one operating segment with three reporting units: Chemical Light (the operations of CTI, CTSAS and CTS), Specialty Products (the operations of CSP) and Other (the operations of CRI and the parent company Cyalume Technologies Holdings, Inc.). Specialty Productsb goodwill was not considered to be impaired and our Other reporting unit does not have a goodwill asset.
[2]	The fair value of the impaired goodwill asset was determined calculating the excess of the fair value of the reporting unit over the fair values assigned to its assets and liabilities and utilized present value techniques utilizing each reporting unitbs forecasted after-tax cash flows.
[3]	The fair value of the impaired patent asset was determined using the brelief from royaltyb method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the patents, net of estimated income taxes (an income approach).
[4]	The fair value of the impaired trademarks and trade names asset was determined using the brelief from royaltyb method, which calculates the present value of a stream of estimated future royalty payments that an entity would be willing to pay in order to utilize the trademarks and trade names, net of estimated income taxes (an income approach).
[5]	The fair value of the impaired non-compete agreement asset was determined using the bcomparative business valuationb method, which compares the present value of two streams of the reporting unitbs estimated future cash flows; one stream assuming the non-compete agreements are in place and the other stream assuming the agreements are not in place (an income approach).

Recovered_Sheet5

Supplemental Disclosure Of Cash Flow Information (Cash Paid for Interest and Income Taxes) (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Interest	$592	$1,693
Income taxes	$244	$133

Recovered_Sheet6

Supplemental Disclosure Of Cash Flow Information (Non-Cash Investing and Financing Activities) (Detail) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 30, 2014
Non-Cash Investing And Financing Activities [Line Items]
Adjustment to warrant liability upon warrant exercise	$44,000	$0
Issuance of 350,000 shares to JFC in connection with settling a contingent consideration liability resulting from the acquisition of CSP	241,000	0
Issuance of 242,308 shares to related party	157,000	0
Warrants liability recorded in connection with common and preferred warrants	0	5,607,000
Litigation award payable accounted for as a receivable due from related party	0	134,000
Amendment and adjustment to the fair value of warrants issued in conjunction with issuance of subordinated term loan recorded within warrant liability	0	241,000	-94,000
Series A Convertible Preferred stock [Member]
Non-Cash Investing And Financing Activities [Line Items]
Preferred stock dividends	509,000	55,000		-2,400,000
Issuance of 242,308 shares to related party	0
Series C Preferred Stock [Member]
Non-Cash Investing And Financing Activities [Line Items]
Preferred stock dividends	-103,000	0
Issuance of 242,308 shares to related party	0
Series A Series B and Series C Preferred stock [Member]
Non-Cash Investing And Financing Activities [Line Items]
Preferred stock dividends	$4,921,000	$4,000,000

Supplemental_Disclosure_Of_Cas2

Supplemental Disclosure Of Cash Flow Information (Non-Cash Investing and Financing Activities) (Parenthetical) (Detail)	12 Months Ended
	Dec. 31, 2014
Selway Capital, LLC [Member]
Non-Cash Investing And Financing Activities [Line Items]
Stock Issued During Period, Shares, New Issues	242,308
Cyalume Specialty Products [Member]
Non-Cash Investing And Financing Activities [Line Items]
Stock Issued During Period Shares Contingent Consideration Liability	350,000

Subsequent_Events_Additional_I

Subsequent Events (Additional Information) (Detail)	Dec. 31, 2014	Dec. 31, 2013	Feb. 19, 2015
Subsequent Event [Line Items]
Common Stock, Shares Authorized	100,000,000	100,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Common Stock, Shares Authorized			150,000,000

Valuation_And_Qualifying_Accou

Valuation And Qualifying Accounts (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Allowance for Doubtful Accounts [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$44		$155
Charged to costs and expenses	12		2
Deductions	-34	[1]	-113	[1]
Balance at End of Period	22		44
Deferred Tax Asset Valuation Allowance [Member]
Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	5,922		3,874
Charged to costs and expenses	7,172		2,048
Deductions	0		0
Balance at End of Period	$13,094		$5,922

[1]	(1) Write-offs and recoveries